<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Fever and rash in immunocompromised patients without HIV infection</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Fever and rash in immunocompromised patients without HIV infection</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Fever and rash in immunocompromised patients without HIV infection</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Fred A Lopez, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Charles V Sanders, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Eric Bow, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Milana Bogorodskaya, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> May 25, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>At least 20 percent of immunocompromised hosts will develop skin lesions, frequently accompanied by fever [<a href="#rid1">1-3</a>]. Immunocompromising diseases can cause multiple defects in host defenses, which, in turn, lead to heightened susceptibility to various types of infections. Knowledge of these immune defects and the specific associated infections can assist the clinician in the initial evaluation and management of the immunocompromised patient with skin lesions. These lesions sometimes reflect disseminated infection; evaluation of the skin may provide the most rapid diagnosis and thus may be lifesaving.</p><p>Some of the common infectious agents and dermatologic manifestations observed in selected immunodeficient states will be reviewed here. Fever and rash in immunocompetent patients and human immunodeficiency virus (HIV)-infected individuals are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/2744.html" rel="external">"Fever and rash in the immunocompetent patient"</a> and  <a class="medical medical_review" href="/z/d/html/3703.html" rel="external">"Fever and rash in patients with HIV"</a>.)</p><p class="headingAnchor" id="H956588753"><span class="h1">TYPES OF IMMUNOCOMPROMISE</span><span class="headingEndMark"> — </span>Underlying diseases that affect various host defenses may predispose the patient to different types of infections. This section provides a brief overview of the different categories of immunocompromise and the types of pathogens that are most likely to affect patients in each category. It is not intended to provide comprehensive details on the immunology of each condition or an exhaustive list of infections that each type of host might experience. Following this overview of immunocompromising conditions, pathogens that most frequently cause fever and rash in immunocompromised hosts will be discussed.</p><p class="headingAnchor" id="H2"><span class="h2">Neutropenia or neutrophil dysfunction</span><span class="headingEndMark"> — </span>Patients with prolonged or profound neutropenia or neutrophil dysfunction are at increased risk for developing infections with a variety of organisms, including gram-positive, gram-negative, and anaerobic bacteria, as well as fungi.</p><p>The most common cause of neutropenia is the administration of chemotherapeutic agents to patients with cancer. However, a number of other conditions also lead to neutrophil depletion or dysfunction, including acute myeloproliferative disorders, myelodysplastic syndromes, aplastic anemia, congenital or cyclic neutropenia, overwhelming sepsis, Felty syndrome, chronic granulomatous disease, or receipt of certain other drugs including <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">azathioprine</a>, <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">vancomycin</a>, sulfonamides, <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">mycophenolate</a> mofetil, <a class="drug drug_general" data-topicid="8485" href="/z/d/drug information/8485.html" rel="external">ganciclovir</a>, and tumor necrosis factor (TNF)-alpha inhibitors.</p><p>Infections may be difficult to appreciate because induration and erythema may not be present secondary to blunting of the host inflammatory response, although characteristic skin manifestations such as ecthyma gangrenosum may occur. (See  <a class="medical medical_review" href="/z/d/html/16708.html" rel="external">"Overview of neutropenic fever syndromes"</a> and  <a class="medical medical_review" href="/z/d/html/16139.html" rel="external">"Diagnostic approach to the adult cancer patient with neutropenic fever", section on 'Skin and mucous membranes'</a>.)</p><p class="headingAnchor" id="H956588867"><span class="h2">Humoral immune dysfunction</span><span class="headingEndMark"> — </span>Patients with humoral immune dysfunction, particularly primary immunoglobulin and complement deficiencies, are at risk for certain bacterial, viral, and parasitic infections, particularly infections with encapsulated bacteria such as <em>Streptococcus pneumoniae</em>, <em>Neisseria meningitidis, </em>and<em> Haemophilus influenzae</em>. Other frequent pathogens include <em>Salmonella </em>spp, <em>Mycoplasma </em>spp, <em>Giardia </em>spp, rotavirus, and enteroviruses [<a href="#rid4">4</a>].</p><p>This group of disorders includes hypogammaglobulinemia states, which can be congenital or due to conditions such as multiple myeloma, Waldenström macroglobulinemia, common variable immune deficiency, nephrotic syndrome, non-Hodgkin lymphoma, and chronic lymphocytic leukemia, as well as antibody-depleting therapies such as plasmapheresis and administration of anti-B cell monoclonal antibody therapy [<a href="#rid5">5</a>]. (See  <a class="medical medical_review" href="/z/d/html/3914.html" rel="external">"Primary humoral immunodeficiencies: An overview"</a> and  <a class="medical medical_review" href="/z/d/html/95716.html" rel="external">"Risk of infections in patients with chronic lymphocytic leukemia"</a>.)</p><p class="headingAnchor" id="H956588887"><span class="h2">Splenic dysfunction</span><span class="headingEndMark"> — </span>Patients without a spleen or with hypofunction of the spleen are at increased risk for infection due to defects in antibody production, decreased ability to remove bacteria from the blood, and decreased production of important opsonin-associated proteins like tuftsin [<a href="#rid6">6</a>]. Conditions associated with functional hyposplenia include systemic lupus erythematosus (SLE), rheumatoid arthritis, graft-versus-host disease, amyloidosis, celiac disease, ulcerative colitis, sickle cell anemia, hereditary spherocytosis, and hemoglobin SC disease [<a href="#rid7">7</a>].</p><p>Asplenic and hyposplenic patients are particularly susceptible to infections with encapsulated bacteria (<em>S. pneumoniae</em>, <em>N. meningitidis, H. influenzae</em>) and may develop overwhelming sepsis with these organisms as well as <em>Capnocytophaga</em> spp (associated with dog or cat bites), Enterobacteriaceae, group A and B streptococci, and others. These patients are also at increased risk for severe babesiosis. (See  <a class="medical medical_review" href="/z/d/html/1404.html" rel="external">"Clinical features, evaluation, and management of fever in patients with impaired splenic function"</a>.)</p><p class="headingAnchor" id="H956589036"><span class="h2">Cell-mediated immune dysfunction</span><span class="headingEndMark"> — </span>Patients with cell-mediated immune (CMI) dysfunction are at increased risk of infection with a myriad of intracellular bacteria and mycobacteria, viruses, fungi, and parasites.</p><p>Conditions other than HIV that are associated with CMI dysfunction include DiGeorge syndrome, Hodgkin lymphoma, lymphocytic leukemia, receipt of total lymphoid irradiation, pregnancy, development of anti-interferon-gamma autoantibodies, defects in the interferon-gamma pathway, and receipt of drugs such as glucocorticoids, <a class="drug drug_general" data-topicid="9971" href="/z/d/drug information/9971.html" rel="external">tacrolimus</a>, <a class="drug drug_general" data-topicid="9630" href="/z/d/drug information/9630.html" rel="external">methotrexate</a>, thymoglobulin, and <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a> (such as after organ transplantation or hematopoietic cell transplantation).</p><p>Fever and rash in HIV-infected individuals are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/3703.html" rel="external">"Fever and rash in patients with HIV"</a>.)</p><p class="headingAnchor" id="H956589272"><span class="h2">Tumor necrosis factor-alpha inhibitors</span><span class="headingEndMark"> — </span>TNF-alpha inhibitors including <a class="drug drug_general" data-topicid="8925" href="/z/d/drug information/8925.html" rel="external">etanercept</a>, <a class="drug drug_general" data-topicid="8583" href="/z/d/drug information/8583.html" rel="external">adalimumab</a>, <a class="drug drug_general" data-topicid="8984" href="/z/d/drug information/8984.html" rel="external">infliximab</a>, <a class="drug drug_general" data-topicid="8644" href="/z/d/drug information/8644.html" rel="external">certolizumab pegol</a>, and <a class="drug drug_general" data-topicid="9086" href="/z/d/drug information/9086.html" rel="external">golimumab</a> are being used with increased frequency in the treatment of patients with inflammatory disorders such as inflammatory bowel disease, rheumatoid arthritis, psoriasis, and seronegative spondyloarthropathies. These agents interfere with cell-mediated host defenses against intracellular pathogens, and adverse effects include serious bacterial, mycobacterial, fungal, viral, and parasitic infections [<a href="#rid8">8-10</a>].</p><p>Pathogens that have been reported to cause fever and rash in patients taking TNF-alpha inhibitors include <em>Nocardia </em>spp [<a href="#rid11">11,12</a>], <em>Mycobacterium tuberculosis</em> and nontuberculous mycobacteria [<a href="#rid13">13-16</a>], <em>Cryptococcus</em> spp [<a href="#rid17">17,18</a>], endemic fungi such as <em>Histoplasma</em> and <em>Coccidioides</em> spp [<a href="#rid19">19-21</a>], and <em>Leishmania</em> spp [<a href="#rid22">22-24</a>]. Invasive fungal infections secondary to <em>Candida</em> and <em>Aspergillus</em> have also been reported [<a href="#rid25">25</a>]. The data are conflicting as to whether the risk for herpes zoster is greater with TNF-alpha inhibitors when compared with other nonbiologic disease-modifying antirheumatic drugs. Hepatitis B virus infections can reactivate during treatment with these agents. (See  <a class="medical medical_review" href="/z/d/html/1411.html" rel="external">"Risk of mycobacterial infection associated with biologic agents and JAK inhibitors"</a> and  <a class="medical medical_review" href="/z/d/html/1410.html" rel="external">"Tumor necrosis factor-alpha inhibitors: Bacterial, viral, and fungal infections"</a> and  <a class="medical medical_review" href="/z/d/html/5689.html" rel="external">"Cutaneous leishmaniasis: Clinical manifestations and diagnosis", section on 'CL in immunocompromised hosts'</a>.)</p><p class="headingAnchor" id="H956589676"><span class="h2">Cirrhosis</span><span class="headingEndMark"> — </span>Patients with cirrhosis can have immune deficits that include impaired phagocytosis and chemotaxis, decreased complement levels, and poor opsonization. Cirrhotic patients are particularly vulnerable to skin and soft tissue infections due to <em>Vibrio vulnificus </em>and <em>Vibrio parahaemolyticus</em> after consumption of raw shellfish or exposure to bodies of water containing the organisms (see  <a class="medical medical_review" href="/z/d/html/3128.html" rel="external">"Vibrio vulnificus infection"</a>). Other gram-negative organisms to consider in cirrhosis-associated necrotizing skin and soft tissue infections include <em>Aeromonas</em> species and <em>Klebsiella</em> species [<a href="#rid26">26</a>].</p><p class="headingAnchor" id="H956589823"><span class="h2">Diabetes mellitus</span><span class="headingEndMark"> — </span>Defects in immune function in diabetics include depressed neutrophil and T cell function [<a href="#rid27">27,28</a>]. Skin and soft tissue infections, especially of the feet, are common infectious complications of diabetes and may be exacerbated by peripheral vascular disease and neuropathy. These include ulcers, abscesses (including carbuncles and furuncles), cellulitis, and necrotizing infections. Superficial necrotizing infections involve epifascial soft tissue or superficial fascia; the microbiology may be monomicrobial or polymicrobial and includes anaerobes, aerobic staphylococci and streptococci, and/or aerobic gram-negative bacilli. (See  <a class="medical medical_review" href="/z/d/html/7651.html" rel="external">"Clinical manifestations, diagnosis, and management of diabetic infections of the lower extremities"</a>.)</p><p>Diabetes mellitus is also a risk factor for polymicrobial necrotizing fasciitis of the perineum (Fournier gangrene), which typically results from breaches in the urethral or gastrointestinal mucosa [<a href="#rid29">29</a>]. Deep necrotizing infections can also involve the deep muscle compartments and include clostridial and nonclostridial myonecrosis and necrotizing fasciitis. (See  <a class="medical medical_review" href="/z/d/html/7672.html" rel="external">"Clostridial myonecrosis"</a> and  <a class="medical medical_review" href="/z/d/html/7662.html" rel="external">"Necrotizing soft tissue infections"</a>.)</p><p>Diabetic ketoacidosis is an important risk factor for the development of rhino-orbital-cerebral mucormycosis  (<a class="graphic graphic_picture graphicRef107467" href="/z/d/graphic/107467.html" rel="external">picture 1</a> and <a class="graphic graphic_picture graphicRef107466" href="/z/d/graphic/107466.html" rel="external">picture 2</a>) [<a href="#rid30">30</a>]. Cutaneous mucormycosis, most commonly following trauma to the skin and involving the extremities, can also occur in diabetics (and in those with organ transplantation, leukemia, and neutropenia) [<a href="#rid31">31</a>]. (See  <a class="medical medical_review" href="/z/d/html/2465.html" rel="external">"Mucormycosis (zygomycosis)"</a>.)</p><p class="headingAnchor" id="H956589930"><span class="h2">Systemic lupus erythematosus</span><span class="headingEndMark"> — </span>SLE can result in defects in complement, neutrophil, immunoglobulin, T cell, and splenic/reticuloendothelial function, and therapy for SLE (including glucocorticoids, <a class="drug drug_general" data-topicid="9308" href="/z/d/drug information/9308.html" rel="external">cyclophosphamide</a>, <a class="drug drug_general" data-topicid="9670" href="/z/d/drug information/9670.html" rel="external">mycophenolate</a> mofetil, <a class="drug drug_general" data-topicid="9616" href="/z/d/drug information/9616.html" rel="external">rituximab</a>, <a class="drug drug_general" data-topicid="9217" href="/z/d/drug information/9217.html" rel="external">cyclosporine</a>, and <a class="drug drug_general" data-topicid="9026" href="/z/d/drug information/9026.html" rel="external">azathioprine</a>) also produces immunosuppression [<a href="#rid32">32,33</a>]. Skin infections have been reported in as many as 34 percent of patients with SLE [<a href="#rid34">34-36</a>]. These infections include cellulitis, abscesses, ulcers, and necrotizing fasciitis [<a href="#rid35">35,37-39</a>].</p><p>Etiologic agents of skin infection include <em>Staphylococcus aureus</em>, group A <em>Streptococcus</em>, varicella-zoster virus, and herpes simplex virus; <em>Escherichia coli</em>, <em>Candida</em> spp, <em>Cryptococcus </em>spp, agents of mucormycosis, and mycobacterial species are less commonly reported. Patients with SLE also appear to be at increased risk for skin and soft tissue infections caused by <em>S. pneumoniae</em> [<a href="#rid40">40</a>]. (See  <a class="medical medical_review" href="/z/d/html/4668.html" rel="external">"Clinical manifestations and diagnosis of systemic lupus erythematosus in adults", section on 'Clinical manifestations'</a>.)</p><p class="headingAnchor" id="H956590169"><span class="h1">INFECTIOUS CAUSES</span><span class="headingEndMark"> — </span>The following section reviews different types of pathogens and their cutaneous manifestations as well as the types of immunocompromised hosts in which they are most likely to occur. It is important to note, however, that infection with these pathogens is not limited to the groups mentioned below.</p><p class="headingAnchor" id="H3"><span class="h2">Bacterial infections</span></p><p class="headingAnchor" id="H3276653221"><span class="h3">Staphylococci</span><span class="headingEndMark"> — </span><em>Staphylococcus</em> species, especially <em>S. aureus</em>, is commonly implicated as a cause of skin and soft tissue infections, presenting as cellulitis, a macular or maculopapular rash, a localized painful erythematous rash, or, less commonly, as subcutaneous abscesses or ecthyma gangrenosum-like lesions [<a href="#rid41">41</a>]. Patients with diabetes mellitus are also at increased risk for <em>S. aureus</em> infections manifesting as furuncles, carbuncles, and abscesses. (See  <a class="medical medical_review" href="/z/d/html/2135.html" rel="external">"Clinical manifestations of Staphylococcus aureus infection in adults", section on 'Skin and soft tissue infection'</a> and  <a class="medical medical_review" href="/z/d/html/110529.html" rel="external">"Cellulitis and skin abscess: Epidemiology, microbiology, clinical manifestations, and diagnosis"</a>.)</p><p class="headingAnchor" id="H2148233397"><span class="h3">Streptococci</span><span class="headingEndMark"> — </span>Several streptococcal species cause skin and soft tissue infections in immunocompromised patients:</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Bacteremia due to viridans group streptococci has increased in frequency in neutropenic patients and generally arises when chemotherapy damages the normal barrier of the oral mucosa [<a href="#rid42">42-45</a>]. Cutaneous manifestations include erythema, maculopapular rash(es), erythema multiforme, petechiae, and purpura; desquamation of palms and/or soles may also be observed [<a href="#rid46">46,47</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><em>Streptococcus pyogenes</em> (group A <em>Streptococcus</em>) should be considered as a potential cause of skin and soft tissue infection in both immunocompetent and immunocompromised patients. Presentations range from superficial infections including cellulitis and erysipelas to deep invasive infections including necrotizing fasciitis with toxic shock syndrome.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Risk factors for invasive pneumococcal infections include alcohol abuse, HIV infection, splenectomy, connective tissue disease including systemic lupus erythematosus, glucocorticoid use, diabetes mellitus, and injection drug use [<a href="#rid48">48</a>]. In patients with splenic dysfunction, <em>Streptococcus pneumoniae</em> can cause cellulitis, pyomyositis, subcutaneous abscess, peripheral gangrene, and livedo reticularis/acrocyanosis. In patients with disseminated intravascular coagulation and overwhelming postsplenectomy sepsis caused by <em>S. pneumoniae</em>, petechial and purpuric lesions may progress to hemorrhagic bullae and peripheral gangrene known as purpura fulminans  (<a class="graphic graphic_picture graphicRef53920" href="/z/d/graphic/53920.html" rel="external">picture 3</a> and <a class="graphic graphic_picture graphicRef57103" href="/z/d/graphic/57103.html" rel="external">picture 4</a>). Pneumococcal cellulitis and necrotizing fasciitis have been described in patients with systemic lupus erythematosus, nephrotic syndrome, cirrhosis, diabetes mellitus, and hematologic disorders such as multiple myeloma [<a href="#rid38">38,40,49</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In nonpregnant adults, risk factors for invasive disease with <em>Streptococcus agalactiae</em> (group B <em>Streptococcus</em>) include diabetes mellitus, liver disease, renal disease, and cancer, among others. Skin and soft tissue infections caused by group B <em>Streptococcus</em> are commonly associated with invasive disease and include cellulitis, erysipelas, infected foot ulcers, infected pressure ulcers, and necrotizing fasciitis with toxic shock-like syndrome [<a href="#rid50">50,51</a>].</p><p></p><p class="headingAnchor" id="H2582165849"><span class="h3">Clostridium species</span><span class="headingEndMark"> — </span>Bloodstream infections with <em>Clostridium septicum, Clostridium perfringens</em>,<em> </em>and <em>Clostridium tertium</em> can be seen in neutropenic patients with gastrointestinal, genitourinary, and hematologic malignancies. <em>C. septicum </em>infection in particular is associated with gastrointestinal tumors. Associated skin and soft tissue infections include abscesses, spreading cellulitis, and myonecrosis with possible associated ecchymoses and bullae formation (ie, gas gangrene). The last two entities are often associated with a rapidly progressive and fatal outcome [<a href="#rid52">52,53</a>]. Both <em>C. septicum </em>and <em>C. perfringens </em>can cause massive, rapidly progressive toxin-mediated hemolysis that is associated with mortality rates &gt;70 percent [<a href="#rid54">54,55</a>]. Gram stain of aspirated fluid and histopathology of infected tissue will frequently reveal characteristic gram-positive "boxcar-like" rods with a dearth of polymorphonuclear leukocytes  (<a class="graphic graphic_picture graphicRef54494" href="/z/d/graphic/54494.html" rel="external">picture 5</a> and <a class="graphic graphic_picture graphicRef80492" href="/z/d/graphic/80492.html" rel="external">picture 6</a>). (See  <a class="medical medical_review" href="/z/d/html/7672.html" rel="external">"Clostridial myonecrosis"</a>.)</p><p class="headingAnchor" id="H4"><span class="h3">Pseudomonas aeruginosa</span><span class="headingEndMark"> — </span><em>Pseudomonas aeruginosa</em> is a feared nosocomial pathogen in immunocompromised hosts and is especially common in neutropenic patients with cancer, although the incidence of bacteremia due to this pathogen has decreased in recent years in this group, concomitant with a rise in gram-positive organisms [<a href="#rid56">56,57</a>].</p><p>Cutaneous manifestations of pseudomonal bacteremia have been reported to occur in up to almost one-third of cases, particularly in neutropenic patients; lesions include abscesses, folliculitis, cellulitis, necrotizing fasciitis, vesicles, maculopapular or subcutaneous nodules, plaques, bullae, pustules, petechiae, and ecthyma gangrenosum [<a href="#rid46">46,58-62</a>]. (See  <a class="medical medical_review" href="/z/d/html/7643.html" rel="external">"Pseudomonas aeruginosa skin and soft tissue infections"</a>.)</p><p>Initially erythematous, painless, and macular, ecthyma gangrenosum lesions evolve into areas of induration that develop into pustules and/or bullae  (<a class="graphic graphic_picture graphicRef114332" href="/z/d/graphic/114332.html" rel="external">picture 7</a>). Ultimately, these lesions become ulcerative with a necrotic center and hemorrhagic border  (<a class="graphic graphic_picture graphicRef80582" href="/z/d/graphic/80582.html" rel="external">picture 8</a>). Ecthyma lesions typically progress rapidly (within 12 to 18 hours).</p><p>Classically, ecthyma gangrenosum lesions are found in the axilla, perineum, or trunk. Once thought to be pathognomonic of <em>P. aeruginosa </em>bacteremia, ecthyma gangrenosum-like lesions can also be caused by gram-positive organisms such as <em>S. pyogenes</em> and <em>S. aureus</em>, other gram-negative organisms (eg, <em>Stenotrophomonas maltophilia</em>, <em>Aeromonas hydrophila</em>, Enterobacteriaceae), fungi (eg, <em>Fusarium</em>, <em>Mucor</em>, <em>Candida</em>, and <em>Aspergillus </em>spp), and herpes simplex virus (HSV) [<a href="#rid60">60,63-68</a>]. (See  <a class="medical medical_review" href="/z/d/html/2136.html" rel="external">"Pseudomonas aeruginosa bacteremia and endocarditis", section on 'Clinical features'</a> and  <a class="medical medical_review" href="/z/d/html/2465.html" rel="external">"Mucormycosis (zygomycosis)", section on 'Cutaneous mucormycosis'</a> and  <a class="medical medical_review" href="/z/d/html/16218.html" rel="external">"Clinical manifestations and diagnosis of Fusarium infection", section on 'Cutaneous lesions'</a> and  <a class="medical medical_review" href="/z/d/html/2462.html" rel="external">"Clinical manifestations and diagnosis of candidemia and invasive candidiasis in adults", section on 'Clinical manifestations'</a>.)</p><p>Of note, ecthyma gangrenosum lesions due to <em>P. aeruginosa</em> can develop in immunocompromised hosts in the absence of bacteremia [<a href="#rid69">69,70</a>].</p><p class="headingAnchor" id="H5"><span class="h3">Stenotrophomonas maltophilia</span><span class="headingEndMark"> — </span><em>S. maltophilia</em> has become a more common gram-negative nosocomial pathogen in neutropenic patients, particularly in patients with underlying hematologic malignancies. Mucocutaneous and soft tissue infections caused by this organism include primary cellulitis (often associated with catheter use), metastatic cellulitis with associated tender and firm nodules, multiple subcutaneous lesions, ecthyma gangrenosum, purpura, necrosis, and ulcers of the oral cavity [<a href="#rid71">71-76</a>]. (See  <a class="medical medical_review" href="/z/d/html/13961.html" rel="external">"Stenotrophomonas maltophilia"</a>.)</p><p class="headingAnchor" id="H6"><span class="h3">Aeromonas hydrophila</span><span class="headingEndMark"> — </span><em>A. hydrophila</em> can cause extraintestinal infection including bacteremia and skin and soft tissue infections in neutropenic hosts. Although these infections may result from fresh- or saltwater exposure, nosocomial acquisition is more common. Cutaneous lesions include cellulitis  (<a class="graphic graphic_picture graphicRef70986" href="/z/d/graphic/70986.html" rel="external">picture 9</a>), which may be extensive, purpura, ulcers, ecchymoses, necrosis, and ecthyma gangrenosum [<a href="#rid46">46</a>]. (See  <a class="medical medical_review" href="/z/d/html/3138.html" rel="external">"Aeromonas infections"</a>.)</p><p class="headingAnchor" id="H39196261"><span class="h3">Vibrio vulnificus/Vibrio parahaemolyticus</span><span class="headingEndMark"> — </span>As mentioned above, patients with cirrhosis are susceptible to infections with <em>V. vulnificus </em>and <em>V. parahaemolyticus,</em> particularly after eating raw shellfish, especially oysters, or after exposure to contaminated seawater or flood waters [<a href="#rid77">77-80</a>]. Infections can present as overwhelming sepsis, frequently with associated skin lesions.</p><p>Skin lesions are usually found on the extremities, beginning as a cellulitis before developing into hemorrhagic vesicular or bullous lesions  (<a class="graphic graphic_picture graphicRef63423" href="/z/d/graphic/63423.html" rel="external">picture 10</a>) and ulcers; necrotizing fasciitis with associated septic shock can occur  (<a class="graphic graphic_picture graphicRef57932" href="/z/d/graphic/57932.html" rel="external">picture 11</a> and <a class="graphic graphic_picture graphicRef51674" href="/z/d/graphic/51674.html" rel="external">picture 12</a>) [<a href="#rid81">81,82</a>]. Similar necrotizing cutaneous lesions can be caused by <em>Aeromonas</em> spp and <em>Escherichia coli</em> [<a href="#rid83">83,84</a>]. (See  <a class="medical medical_review" href="/z/d/html/3128.html" rel="external">"Vibrio vulnificus infection"</a>.)</p><p class="headingAnchor" id="H39196434"><span class="h2">Nocardiosis</span><span class="headingEndMark"> — </span>Skin lesions associated with <em>Nocardia</em> spp in immunocompromised hosts are usually due to disseminated disease originating in the lungs; skin involvement occurs in approximately 10 to 40 percent of cases [<a href="#rid85">85-90</a>]. Often located on the extremities and trunk, these lesions are typically subcutaneous abscesses, panniculitis/cellulitis, pustules, or nodules with or without ulcerations  (<a class="graphic graphic_picture graphicRef54114" href="/z/d/graphic/54114.html" rel="external">picture 13</a>) [<a href="#rid85">85</a>]. Biopsy of the lesion reveals gram-positive or partially acid-fast organisms that are described as beaded, branching, and filamentous. (See  <a class="medical medical_review" href="/z/d/html/5515.html" rel="external">"Nocardia infections: Epidemiology, clinical manifestations, and diagnosis", section on 'Skin'</a> and  <a class="medical medical_review" href="/z/d/html/5514.html" rel="external">"Nocardia infections: Clinical microbiology and pathogenesis", section on 'Microbiology'</a>.)</p><p class="headingAnchor" id="H39196573"><span class="h2">Mycobacteria</span><span class="headingEndMark"> — </span>A variety of mycobacteria can cause skin infections in immunocompromised hosts [<a href="#rid91">91</a>]. Detection of mycobacterial species from infected lesions is important for establishing the diagnosis.</p><p class="headingAnchor" id="H39196629"><span class="h3">Mycobacterium tuberculosis</span><span class="headingEndMark"> — </span>The skin as a site of extrapulmonary tuberculosis is uncommon. The manifestations of cutaneous tuberculosis depend upon the route of infection in addition to the immune status of the host [<a href="#rid92">92,93</a>]. Although most primary tuberculosis is acquired through inhalation, exogenously acquired disease typically results from direct percutaneous inoculation. The tuberculosis chancre that results from primary inoculation of <em>M. tuberculosis</em> initially presents as a painless papulonodular lesion that later ulcerates. Painless localized lymphadenopathy is characteristic. Initially <a class="drug drug_general" data-topicid="10029" href="/z/d/drug information/10029.html" rel="external">tuberculin skin test</a> (TST) negative, TST positivity develops later in the disease. Tuberculosis verrucosa cutis is also a result of direct inoculation but differs from the tuberculous chancre because the host is an immunocompetent individual previously infected with tuberculosis. These patients are TST positive early in the course of disease. Initially papular, skin lesions later become verrucous plaques, and localized lymphadenopathy is typically absent.</p><p>During acute disease, skin lesions due to exogenously acquired <em>M. tuberculosis </em>are often described as red-brown papules, vesicles, nodules, macules, or purpura. Cutaneous manifestations of reactivated tuberculous disease include subcutaneous abscesses  (<a class="graphic graphic_picture graphicRef65877" href="/z/d/graphic/65877.html" rel="external">picture 14</a>), papules, and nodules  (<a class="graphic graphic_picture graphicRef53596" href="/z/d/graphic/53596.html" rel="external">picture 15</a>) [<a href="#rid94">94</a>]. Lupus vulgaris describes skin manifestations (plaque, hypertrophic, papulonodular, and ulcerative types) associated with hematogenous, lymphatic, or contiguous spread of <em>M. tuberculosis </em> (<a class="graphic graphic_picture graphicRef64828" href="/z/d/graphic/64828.html" rel="external">picture 16</a>). Scrofuloderma describes a nodule that ulcerates over a contiguous focus of tuberculous disease  (<a class="graphic graphic_picture graphicRef72008" href="/z/d/graphic/72008.html" rel="external">picture 17</a>). The characteristic site of this cutaneous manifestation is the neck, reflecting involvement of the underlying cervical lymph nodes. (See  <a class="medical medical_review" href="/z/d/html/15866.html" rel="external">"Cutaneous manifestations of tuberculosis"</a>.)</p><p>It is important to note that immunocompromised hosts, particularly those with depressed cell-mediated immunity, may not mount a response to the TST or the interferon-gamma release assay (IGRA), so a negative TST or IGRA should not dissuade clinicians from attempting to establish a diagnosis of tuberculosis. (See  <a class="medical medical_review" href="/z/d/html/15866.html" rel="external">"Cutaneous manifestations of tuberculosis", section on 'Diagnostic approach'</a> and  <a class="medical medical_review" href="/z/d/html/15866.html" rel="external">"Cutaneous manifestations of tuberculosis", section on 'Specific tests'</a>.)</p><p class="headingAnchor" id="H39196828"><span class="h3">Nontuberculous mycobacteria</span><span class="headingEndMark"> — </span>Nontuberculous mycobacteria also cause skin infections. Skin lesions in the immunocompromised host often develop in the absence of traumatic injury (in contrast with immunocompetent patients). </p><p><em>Mycobacterium marinum</em> is found in fresh and salt water, including fish tanks. Skin lesions include either a localized papule or nodule at the site of inoculation (with or without lymphangitis) or, when disseminated, multiple potentially ulcerated skin nodules  (<a class="graphic graphic_picture graphicRef68569" href="/z/d/graphic/68569.html" rel="external">picture 18</a>), which can develop a sporotrichoid-like pattern [<a href="#rid95">95-97</a>]. </p><p><em>Mycobacterium kansasii</em> usually causes seromas or cellulitis, although subcutaneous nodules, sporotrichoid papules, abscesses, and necrotic papulopustules have also been reported [<a href="#rid98">98</a>].</p><p><em>Mycobacterium haemophilum</em> infections, primarily seen in immunocompromised patients, often involve the skin and underlying soft tissues of the extremities, including extensor surfaces of elbows and legs, likely because the organism grows best at cooler temperatures [<a href="#rid99">99,100</a>]. One review of 23 patients with <em>M. haemophilum</em> infections seen at one institution over 11 years revealed only skin lesions at initial presentation in over 50 percent of these patients [<a href="#rid101">101</a>]. Multiple tender, erythematous/violaceous nodules or papules are initially present before progressing to cutaneous ulcerations [<a href="#rid99">99,102</a>]. </p><p>Skin infections due to rapidly growing mycobacteria (<em>Mycobacterium fortuitum,</em> <em>Mycobacterium chelonae</em>, and <em>Mycobacterium abscessus</em>) include cellulitis, subcutaneous nodules or abscesses (which may break down and drain)  (<a class="graphic graphic_picture graphicRef72386" href="/z/d/graphic/72386.html" rel="external">picture 19</a>), sporotrichoid lesions, and venous catheter-related infections [<a href="#rid103">103,104</a>]. Sternal wound infections with rapidly growing mycobacteria have been described [<a href="#rid105">105</a>]. </p><p>Disseminated <em>Mycobacterium</em> <em>avium</em> complex infections can be seen in immunocompromised patients who are not infected with HIV. In a small series of these patients, 16 percent developed nodular skin lesions [<a href="#rid106">106</a>]. Erythematous papules, lupus-vulgaris-like lesions, and panniculitis have also been reported [<a href="#rid107">107</a>]. (See  <a class="medical medical_review" href="/z/d/html/5347.html" rel="external">"Rapidly growing mycobacterial infections: Mycobacteria abscessus, chelonae, and fortuitum"</a>.)</p><p class="headingAnchor" id="H9"><span class="h2">Fungal infections</span><span class="headingEndMark"> — </span>Important causes of fungal infection are broadly divided into the categories of yeasts (including <em>Candida</em> spp, <em>Trichosporon</em> spp, and <em>Cryptococcus</em> spp), molds (including <em>Aspergillus</em> spp, <em>Fusarium</em> spp, the agents of mucormycosis, dematiaceous fungi, and dermatophytes), and dimorphic fungi (including the endemic mycoses due to <em>Histoplasma capsulatum</em>, <em>Coccidioides </em>spp, <em>Blastomyces dermatitidis, Paracoccidioides </em>spp, and <em>Talaromyces </em>[formerly <em>Penicillium</em>] <em>marneffei</em>). Patients with neutropenia due to cancer chemotherapy are particularly susceptible to invasive fungal infections, especially those with neutropenia of greater than seven days' duration and with profound neutropenia (neutrophil count &lt;100 cells/uL) [<a href="#rid108">108</a>]. <em>Candida</em> spp and <em>Aspergillus</em> spp account for most invasive fungal infections during neutropenia. Invasive fungal infections also occur in other types of immunocompromised hosts, including solid organ transplant recipients, hematopoietic cell transplant recipients (especially those with graft-versus-host disease), diabetics with uncontrolled hyperglycemia, patients with defects in cell-mediated immunity, patients receiving a tumor necrosis factor-alpha inhibitor (particularly associated with reactivation of endemic mycoses), and patients receiving glucocorticoids.</p><p class="headingAnchor" id="H10"><span class="h3">Candida species</span><span class="headingEndMark"> — </span><em>Candida</em> spp are commensal organisms of the skin, oropharynx, and gastrointestinal tract. Infections due to <em>Candida</em> spp that involve the skin range from superficial to invasive depending upon underlying host illnesses and comorbidities. Superficial candidal infections of the skin include intertrigo, folliculitis, and balanitis. Oral mucosal candidiasis (thrush) is common in neutropenic patients and in those with altered cellular immune function, including solid organ transplant recipients, and may progress to esophageal candidiasis. Chronic mucocutaneous candidiasis is a heterogeneous group of syndromes with common features including chronic noninvasive <em>Candida</em> infections of the skin, nails, and mucous membranes and associated autoimmune manifestations (most commonly endocrinopathies); it is caused by genetic faults in the immune system. (See  <a class="medical medical_review" href="/z/d/html/2416.html" rel="external">"Overview of Candida infections", section on 'Balanitis'</a> and  <a class="medical medical_review" href="/z/d/html/6876.html" rel="external">"Balanitis in adults"</a> and  <a class="medical medical_review" href="/z/d/html/2427.html" rel="external">"Esophageal candidiasis in adults"</a> and  <a class="medical medical_review" href="/z/d/html/13569.html" rel="external">"Chronic mucocutaneous candidiasis"</a> and  <a class="medical medical_review" href="/z/d/html/115366.html" rel="external">"Intertrigo"</a> and  <a class="medical medical_review" href="/z/d/html/103297.html" rel="external">"Infectious folliculitis", section on 'Fungal folliculitis'</a>.)</p><p>Disseminated candidiasis is most commonly seen in neutropenic patients. <em>C. albicans</em>, <em>C. glabrata</em>, <em>C. tropicalis</em>, <em>C. krusei</em>, <em>C. parapsilosis</em>, <em>C. lusitaniae</em>, and <em>C. kefyr</em> are clinically important <em>Candida</em> species in neutropenic patients [<a href="#rid109">109</a>], particularly those who are not receiving azole antifungal prophylaxis or who have severe oral or gastrointestinal mucositis. Skin lesions accompany invasive candidiasis in approximately 15 percent of patients, dependent on the underlying disease (severity of neutropenia) and infecting species, with <em>C. tropicalis</em>, <em>C. krusei</em>, and <em>C. albicans </em>causing skin lesions most frequently [<a href="#rid95">95,110</a>]. Discrete and erythematous macronodular  (<a class="graphic graphic_picture graphicRef75717" href="/z/d/graphic/75717.html" rel="external">picture 20</a>), pustular  (<a class="graphic graphic_picture graphicRef55977" href="/z/d/graphic/55977.html" rel="external">picture 21</a>), macular, plaque-like, cellulitic, or papular lesions that may develop associated hemorrhage or necrosis are often described  (<a class="graphic graphic_picture graphicRef78188" href="/z/d/graphic/78188.html" rel="external">picture 22</a>) [<a href="#rid111">111</a>]; ecthyma gangrenosum-like lesions and subcutaneous abscesses have also been reported [<a href="#rid63">63,110</a>]. Lesions typically involve the trunk and extremities; they may be scattered and few or numerous. Larger areas of skin involvement have also been observed overlying a muscle abscess  (<a class="graphic graphic_picture graphicRef64945" href="/z/d/graphic/64945.html" rel="external">picture 23</a>). Histopathology from infected tissue reveals characteristic yeast and pseudohyphae. Blood cultures may not be positive for <em>Candida</em> spp in these situations, so diagnosis by skin biopsy is often important. (See  <a class="medical medical_review" href="/z/d/html/2416.html" rel="external">"Overview of Candida infections"</a>.)</p><p class="headingAnchor" id="H39197112"><span class="h3">Trichosporon species</span><span class="headingEndMark"> — </span>Disseminated <em>Trichosporon </em>spp<em> </em>infections resemble invasive candidiasis and have associated skin manifestations in almost one-third of cases [<a href="#rid112">112,113</a>]. These lesions are typically erythematous, nontender, and maculopapular, papulonodular, purpuric, or papulopustular with or without ulceration or central necrosis; they are often found on trunk, extremities, or face [<a href="#rid108">108,114</a>]. Microscopic examination of infected tissue demonstrates hyphae and pseudohyphae, rectangular arthroconidia, and blastoconidia. (See  <a class="medical medical_review" href="/z/d/html/2456.html" rel="external">"Infections due to Trichosporon species and Blastoschizomyces capitatus (Saprochaete capitata)"</a>.)</p><p class="headingAnchor" id="H39197254"><span class="h3">Cryptococcus species</span><span class="headingEndMark"> — </span>Disseminated <em>Cryptococcus </em>infections involve the skin in approximately 10 to 20 percent of cases of <em>Cryptococcus neoformans</em> infection [<a href="#rid115">115</a>], and skin involvement appears to be more common in solid organ transplant recipients than in other immunocompromised hosts with defects in cell-mediated immunity. Skin involvement can also occur in patients with <em>Cryptococcus gattii</em> infections. Although the majority of skin lesions result from disseminated infection, primary cryptococcal skin infections by direct inoculation have also been reported [<a href="#rid116">116</a>].</p><p>The most common cutaneous findings of cryptococcal infections include crusted granulomas, often resembling molluscum contagiosum lesions  (<a class="graphic graphic_picture graphicRef69214" href="/z/d/graphic/69214.html" rel="external">picture 24</a>), papules, pustules, nodules, necrotic ulcers, subcutaneous swellings, abscesses, cellulitis, panniculitis, violaceous dermal plaques, ecchymoses, palpable purpura, and pyoderma gangrenosum, often involving the lower extremities  (<a class="graphic graphic_picture graphicRef50805" href="/z/d/graphic/50805.html" rel="external">picture 25</a>) [<a href="#rid115">115,117-121</a>]. Histopathologic examination of infected tissue for characteristic encapsulated yeast forms and isolation of the organism in culture are used for diagnosis. Cellulitis due to <em>Cryptococcus</em> spp may mimic bacterial cellulitis and may consequently go undiagnosed initially. An episode of cellulitis in a solid organ transplant recipient that does not respond to antibacterial therapy should be investigated for possible cryptococcosis. Necrotizing soft tissue infections, including necrotizing fasciitis and myositis, have been described in solid organ transplant recipients [<a href="#rid122">122</a>]. (See  <a class="medical medical_review" href="/z/d/html/2421.html" rel="external">"Cryptococcus neoformans infection outside the central nervous system", section on 'Clinical manifestations'</a> and  <a class="medical medical_review" href="/z/d/html/85842.html" rel="external">"Cryptococcus gattii infection: Clinical features and diagnosis", section on 'Other features'</a>.)</p><p class="headingAnchor" id="H11"><span class="h3">Aspergillus species</span><span class="headingEndMark"> — </span>Cutaneous disease due to <em>Aspergillus</em> spp may be secondary to disseminated infection that begins after inhalation into the respiratory tract. Lesions may be nodular or initially papulopustular (often erythematous and tender) before ulcerating and developing central necrosis [<a href="#rid123">123</a>]; cellulitic, bullous, and zosteriform lesions have also been described [<a href="#rid124">124,125</a>]. Primary cutaneous infections can occur at intravenous catheter sites or underneath adhesive dressings and contaminated intravenous arm boards [<a href="#rid126">126-128</a>]. Tender, erythematous indurated plaques or bullae at the wound site often progress to a necrotic ulcer with eschar formation [<a href="#rid129">129,130</a>]. The differential diagnosis includes lesions due to <em>Fusarium</em>, the agents of mucormycosis, <em>Aeromonas</em>, and <em>P. aeruginosa</em>. Skin biopsies reveal septate hyphae that branch at acute angles. (See  <a class="medical medical_review" href="/z/d/html/2454.html" rel="external">"Epidemiology and clinical manifestations of invasive aspergillosis"</a>.)</p><p class="headingAnchor" id="H12"><span class="h3">Agents of mucormycosis</span><span class="headingEndMark"> — </span>Members of the Mucoraceae family (eg, <em>Mucor</em>, <em>Rhizopus</em>, and <em>Apophysomyces </em>spp) may cause cutaneous or rhino-orbital-cerebral disease in immunocompromised hosts  (<a class="graphic graphic_picture graphicRef107467" href="/z/d/graphic/107467.html" rel="external">picture 1</a> and <a class="graphic graphic_picture graphicRef107466" href="/z/d/graphic/107466.html" rel="external">picture 2</a>) [<a href="#rid131">131</a>]. Inoculation through traumatized skin or beneath nonsterile occlusive adhesive dressings can result in primary cutaneous infections that initially manifest as papulonodular lesions with erythema and induration [<a href="#rid132">132</a>]. The lesions may progress to necrosis with the formation of a black eschar and surrounding erythema (ecthyma gangrenosum-like) [<a href="#rid133">133</a>]. These lesions may be a source for hematogenous dissemination of disease.</p><p>Lesions associated with disseminated disease (usually from a primary infection in the lungs) can appear nodular, pustular, vesicular, or papular and are subcutaneous in location. Like the primary cutaneous lesions, lesions associated with disseminated infection can also ulcerate and develop an eschar. A skin biopsy reveals broad right-angle branching aseptate hyphae. (See  <a class="medical medical_review" href="/z/d/html/2465.html" rel="external">"Mucormycosis (zygomycosis)"</a>.)</p><p>Erythematous skin lesions with or without necrosis can also be seen overlying affected areas of patients with rhino-orbital-cerebral mucormycosis.</p><p class="headingAnchor" id="H14"><span class="h3">Fusarium species</span><span class="headingEndMark"> — </span>While superficial <em>Fusarium</em> infections commonly occur (in the form of onychomycosis or keratitis), disseminated infection is seen primarily in neutropenic patients, patients with hematologic malignancies, and/or hematopoietic cell transplant recipients with graft-versus-host disease [<a href="#rid134">134</a>]. In a review of 232 immunocompromised patients with cutaneous <em>Fusarium</em> infections, 88 percent of skin lesions reflected disseminated disease [<a href="#rid135">135</a>]. Elsewhere, cutaneous involvement is reported in approximately 70 percent of disseminated <em>Fusarium</em> infections [<a href="#rid136">136,137</a>].</p><p>Metastatic skin lesions include pustules, papules  (<a class="graphic graphic_picture graphicRef55873" href="/z/d/graphic/55873.html" rel="external">picture 26</a>), erythematous or necrotic macules or plaques, erythematous subcutaneous nodules, ulcers  (<a class="graphic graphic_picture graphicRef61489" href="/z/d/graphic/61489.html" rel="external">picture 27</a>), target lesions  (<a class="graphic graphic_picture graphicRef64575" href="/z/d/graphic/64575.html" rel="external">picture 28</a>), ecthyma gangrenosum-like lesions  (<a class="graphic graphic_picture graphicRef54774" href="/z/d/graphic/54774.html" rel="external">picture 29</a>), or, rarely, bullae  (<a class="graphic graphic_picture graphicRef77327" href="/z/d/graphic/77327.html" rel="external">picture 30</a>). <em>Fusarium</em> lesions are often tender, in contrast with those caused by <em>Aspergillus</em>.</p><p>Progressive soft tissue infection can also be seen by contiguous spread from a preexisting area of onychomycosis; <em>Fusarium</em> infection should therefore be considered in neutropenic patients presenting with toe (or, less commonly, finger) paronychia or cellulitis with associated onychomycosis  (<a class="graphic graphic_picture graphicRef50045" href="/z/d/graphic/50045.html" rel="external">picture 31</a> and <a class="graphic graphic_picture graphicRef78755" href="/z/d/graphic/78755.html" rel="external">picture 32</a>).</p><p>Like aspergillosis, infected tissue reveals septate hyaline hyphae that branch at acute angles. Filamentous organisms that can undergo asexual reproduction in vivo, such as <em>Fusarium</em> species and <em>Scedosporium</em> species (including <em>Pseudoallescheria boydii</em>), typically have higher fungal burdens and potential for positive blood cultures and frequent skin lesions in multiple stages of development [<a href="#rid138">138,139</a>]. In one study, blood cultures grew <em>Fusarium</em> in 41 percent of patients [<a href="#rid140">140</a>]. (See  <a class="medical medical_review" href="/z/d/html/2426.html" rel="external">"Mycology, pathogenesis, and epidemiology of Fusarium infection"</a> and  <a class="medical medical_review" href="/z/d/html/16218.html" rel="external">"Clinical manifestations and diagnosis of Fusarium infection"</a>.)</p><p class="headingAnchor" id="H3164495469"><span class="h3">Phaeohyphomycosis</span><span class="headingEndMark"> — </span>Phaeohyphomycosis refers to infection caused by dematiaceous (pigmented) molds. Most infections due to these fungi are noninvasive and superficial. However, invasive complications of <em>Alternaria</em> and <em>Exophiala</em> species-associated infections involving the skin and subcutaneous tissues have been described in immunocompromised hosts [<a href="#rid141">141,142</a>]. Most commonly located on the upper and lower extremities, lesions can be multiple or solitary and include abscesses, plaques, papules, pustules, cellulitis, ulcers, and nodules [<a href="#rid143">143</a>].</p><p class="headingAnchor" id="H39197662"><span class="h3">Endemic fungi</span><span class="headingEndMark"> — </span>Systemic fungal infections can be caused by soil-colonizing fungi that are prevalent in certain areas of the United States and Canada, including <em>B. dermatitidis</em> (south-central, north central, Manitoba and Northwest Ontario, and along the St. Lawrence Seaway), <em>Coccidioides </em>species (southwest), and <em>H. capsulatum</em> (Ohio and Mississippi River valleys, southern Ontario, St. Lawrence River valley, and focal areas on the East Coast). Skin lesions, seen in 40 to 80 percent of patients with extrapulmonary disease, are usually due to disseminated infection [<a href="#rid144">144</a>].</p><p><em>B. dermatitidis</em>-associated skin lesions are most commonly ulcerative, pustular, or verrucous; other manifestations include plaques and subcutaneous nodules  (<a class="graphic graphic_picture graphicRef78481" href="/z/d/graphic/78481.html" rel="external">picture 33</a> and <a class="graphic graphic_picture graphicRef71630" href="/z/d/graphic/71630.html" rel="external">picture 34</a>) [<a href="#rid145">145-147</a>]. Biopsies of these lesions reveal broad-based budding yeast.</p><p>Disseminated <em>Coccidioides</em> infections can result in verrucous or granulomatous papules, nodules, or plaques; cold subcutaneous abscesses, ulcers, and pustules may also develop [<a href="#rid148">148-151</a>]. Microscopic examination of biopsies from skin lesions demonstrates characteristic spherules.</p><p>In patients with histoplasmosis, oropharyngeal lesions are more common than skin lesions  (<a class="graphic graphic_picture graphicRef65657" href="/z/d/graphic/65657.html" rel="external">picture 35</a>). Oral lesions are also common in patients with paracoccidioidomycosis and are seen less commonly in those with blastomycosis. (See  <a class="medical medical_review" href="/z/d/html/2455.html" rel="external">"Pathogenesis and clinical manifestations of disseminated histoplasmosis", section on 'Skin involvement'</a> and  <a class="medical medical_review" href="/z/d/html/2437.html" rel="external">"Clinical manifestations and diagnosis of blastomycosis", section on 'Other sites'</a> and  <a class="medical medical_review" href="/z/d/html/2435.html" rel="external">"Clinical manifestations and diagnosis of chronic paracoccidioidomycosis", section on 'Mucosa'</a>.)</p><p>The skin lesions of disseminated histoplasmosis may take a wide variety of forms including hyperpigmented painless macules, papules  (<a class="graphic graphic_picture graphicRef78902" href="/z/d/graphic/78902.html" rel="external">picture 36</a>), nodules with or without ulceration, pustules, plaques, purpuric lesions, and vasculitic lesions [<a href="#rid152">152-155</a>]. Necrotizing vasculitis mimicking pyoderma gangrenosum and granulomatous panniculitis mimicking erythema nodosum have been described [<a href="#rid156">156,157</a>]. The histopathology of infected skin includes granulomatous inflammation and small budding yeast forms within macrophages. Primary cutaneous histoplasmosis has also been reported [<a href="#rid158">158</a>], although it is much less common than disseminated histoplasmosis with cutaneous manifestations.</p><p>Paracoccidioidomycosis occurs in parts of Central and South America and may be associated with skin lesions, including ulcers, papules, and verrucous lesions  (<a class="graphic graphic_picture graphicRef54429" href="/z/d/graphic/54429.html" rel="external">picture 37</a> and <a class="graphic graphic_picture graphicRef62412" href="/z/d/graphic/62412.html" rel="external">picture 38</a>) [<a href="#rid159">159,160</a>]. In acute/subacute (juvenile) paracoccidioidomycosis, superficial lymph node involvement is most common in the cervical, axillary, and inguinal regions, and draining fistulae may develop  (<a class="graphic graphic_picture graphicRef52733" href="/z/d/graphic/52733.html" rel="external">picture 39</a>).</p><p><em>T.</em> <em>marneffei </em>is endemic in Southeast Asia, southern China, Taiwan, Hong Kong, and northeastern India and can cause disseminated disease including skin involvement in patients with impaired cell-mediated immunity [<a href="#rid161">161</a>]. The classic skin lesion is a papule that then takes on an umbilicated appearance resembling molluscum contagiosum. Of note, one retrospective cohort study showed that patients with non-HIV-associated <em>T. marneffei</em> infection were less likely than HIV-infected patients to have umbilicated papules but more likely to have acute febrile neutrophilic dermatosis (ie, Sweet syndrome) [<a href="#rid162">162</a>]. (See  <a class="medical medical_review" href="/z/d/html/3033.html" rel="external">"Epidemiology and clinical manifestations of Talaromyces (Penicillium) marneffei infection", section on 'Signs and symptoms'</a>.)</p><p><em>Emergomyces</em> (previously <em>Emmonsia) </em>species are more recently reported endemic fungi from Asia, Africa, North America, and Europe that can cause disseminated disease primarily in patients with impaired cell-mediated immunity [<a href="#rid163">163,164</a>]. Disseminated disease frequently manifests cutaneously as pustules, papules, subcutaneous nodules, plaques, and ulcers [<a href="#rid165">165,166</a>].</p><p class="headingAnchor" id="H22"><span class="h2">Viruses</span></p><p class="headingAnchor" id="H39197903"><span class="h3">Herpes simplex virus and varicella-zoster virus</span><span class="headingEndMark"> — </span>Patients with cell-mediated immune dysfunction are at increased risk for reactivation of HSV and varicella-zoster virus (VZV) infections [<a href="#rid41">41</a>], which may be either localized or disseminated. Mucous membrane involvement in the form of oropharyngeal ulcerations is a common manifestation of HSV reactivation. Skin lesions due to HSV in immunocompromised hosts are more likely to be chronic, nonhealing, and extensive; extracutaneous dissemination can occur. Painful vesicular lesions may become ulcerative, hemorrhagic, and necrotic and, in the case of VZV, develop in multiple dermatomes  (<a class="graphic graphic_picture graphicRef58282" href="/z/d/graphic/58282.html" rel="external">picture 40</a> and <a class="graphic graphic_picture graphicRef74420" href="/z/d/graphic/74420.html" rel="external">picture 41</a> and <a class="graphic graphic_picture graphicRef53566" href="/z/d/graphic/53566.html" rel="external">picture 42</a>). In hematopoietic cell transplant recipients, in particular, VZV lesions may be nonvesicular and atypical in appearance (macules, papules, plaques), leading to delays in diagnosis. VZV without rash can also occur, with characteristic hyperesthesia, paresthesias, or neuropathic pain in a dermatomal distribution without visible lesions. Differentiation of HSV and VZV based upon culture, nucleic acid amplification testing, or direct fluorescent antibody staining is helpful in dictating the antiviral therapy dosing as VZV infection requires higher doses than HSV. (See  <a class="medical medical_review" href="/z/d/html/8334.html" rel="external">"Epidemiology, clinical manifestations, and diagnosis of herpes simplex virus type 1 infection"</a> and  <a class="medical medical_review" href="/z/d/html/8327.html" rel="external">"Epidemiology, clinical manifestations, and diagnosis of herpes zoster"</a>.)</p><p class="headingAnchor" id="H39198657"><span class="h3">Hepatitis B virus</span><span class="headingEndMark"> — </span>Hepatitis B virus (HBV) reactivation can occur in solid organ transplant recipients, hematopoietic cell transplant recipients, and patients receiving glucocorticoids or other immunosuppressive therapies such as tumor necrosis factor-alpha inhibitors. Extrahepatic complications of chronic hepatitis B infection include polyarteritis nodosa (PAN) and mixed cryoglobulinemia. Cutaneous manifestations of PAN include palpable purpura, erythematous nodules, ulcers, and livedo reticularis [<a href="#rid167">167</a>]. Mixed cryoglobulinemia can be associated with palpable purpura and ulcers [<a href="#rid168">168</a>]. (See  <a class="medical medical_review" href="/z/d/html/1410.html" rel="external">"Tumor necrosis factor-alpha inhibitors: Bacterial, viral, and fungal infections", section on 'Hepatitis B'</a> and  <a class="medical medical_review" href="/z/d/html/3627.html" rel="external">"Hepatitis B virus: Clinical manifestations and natural history", section on 'Extrahepatic manifestations'</a>.)</p><p class="headingAnchor" id="H39197916"><span class="h3">Other viruses</span><span class="headingEndMark"> — </span>Other viruses that can cause skin manifestations in immunocompromised hosts include cytomegalovirus (ulcerations, nodules, maculopapular rash, vesicles), molluscum contagiosum (umbilicated papules/vesicles), human papillomavirus (verrucous lesions), Epstein-Barr virus (in the form of posttransplant lymphoproliferative disease), hepatitis C virus (leukocytoclastic vasculitis/essential mixed cryoglobulinemia, porphyria cutanea tarda, lichen planus, necrolytic acral erythema), and human herpes virus (HHV-) 8 (in the form of Kaposi sarcoma). (See  <a class="medical medical_review" href="/z/d/html/4033.html" rel="external">"Molluscum contagiosum"</a> and  <a class="medical medical_review" href="/z/d/html/83230.html" rel="external">"Epidemiology, clinical manifestations, and diagnosis of post-transplant lymphoproliferative disorders"</a> and  <a class="medical medical_review" href="/z/d/html/7729.html" rel="external">"Classic Kaposi sarcoma: Clinical features, staging, diagnosis, and treatment"</a>.)</p><p>Viruses that can cause acute fever and rash in any host, including immunocompromised hosts, include HHV-6 and HHV-7 (roseola), measles, rubella, parvovirus, and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2; coronavirus disease 2019 [COVID-19]). Additional viruses that can cause fever and rash in any host and that are associated with specific geographic regions include dengue, chikungunya, Zika virus, Ebola virus, and other causes of hemorrhagic fever. (See  <a class="medical medical_review" href="/z/d/html/8320.html" rel="external">"Clinical manifestations, diagnosis, and treatment of human herpesvirus 6 infection in adults"</a> and  <a class="medical medical_review" href="/z/d/html/16146.html" rel="external">"Human herpesvirus 6 infection in hematopoietic cell transplant recipients"</a> and  <a class="medical medical_review" href="/z/d/html/3021.html" rel="external">"Measles: Clinical manifestations, diagnosis, treatment, and prevention"</a> and  <a class="medical medical_review" href="/z/d/html/8272.html" rel="external">"Clinical manifestations and diagnosis of parvovirus B19 infection"</a> and  <a class="medical medical_review" href="/z/d/html/3025.html" rel="external">"Dengue virus infection: Clinical manifestations and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/3024.html" rel="external">"Chikungunya fever: Epidemiology, clinical manifestations, and diagnosis"</a> and  <a class="medical medical_review" href="/z/d/html/3022.html" rel="external">"Clinical manifestations and diagnosis of Ebola virus disease"</a> and  <a class="medical medical_review" href="/z/d/html/96985.html" rel="external">"Diseases potentially acquired by travel to Central Africa", section on 'Other viral hemorrhagic fevers'</a> and  <a class="medical medical_review" href="/z/d/html/106169.html" rel="external">"Zika virus infection: An overview"</a>.)</p><p>It is important to obtain a travel history from patients presenting with fever and rash. (See  <a class="medical medical_review" href="/z/d/html/3885.html" rel="external">"Approach to illness associated with travel to East Asia"</a> and  <a class="medical medical_review" href="/z/d/html/3886.html" rel="external">"Approach to illness associated with travel to Southeast Asia"</a> and  <a class="medical medical_review" href="/z/d/html/3883.html" rel="external">"Approach to illness associated with travel to Latin America and the Caribbean"</a> and  <a class="medical medical_review" href="/z/d/html/96935.html" rel="external">"Approach to illness associated with travel to South Asia"</a> and  <a class="medical medical_review" href="/z/d/html/97058.html" rel="external">"Approach to illness associated with travel to West Africa"</a> and  <a class="medical medical_review" href="/z/d/html/97008.html" rel="external">"Diseases potentially acquired by travel to Southern Africa"</a> and  <a class="medical medical_review" href="/z/d/html/96975.html" rel="external">"Diseases potentially acquired by travel to East Africa"</a> and  <a class="medical medical_review" href="/z/d/html/96985.html" rel="external">"Diseases potentially acquired by travel to Central Africa"</a> and  <a class="medical medical_review" href="/z/d/html/96960.html" rel="external">"Diseases potentially acquired by travel to North Africa"</a>.)</p><p>Human papillomavirus infections are common in transplant recipients, leading to increased risk for skin, cervical, and anal cancers. Many long-term survivors after solid organ transplantation often have many verruciform lesions and must undergo careful surveillance for skin cancer development. However, these infections are slowly progressive and are not generally seen as a cause of fever and rash. (See  <a class="medical medical_review" href="/z/d/html/8314.html" rel="external">"Human papillomavirus infections: Epidemiology and disease associations"</a>.)</p><p class="headingAnchor" id="H956590176"><span class="h1">NONINFECTIOUS CAUSES</span><span class="headingEndMark"> — </span>Important noninfectious causes of fever and rash in immunocompromised hosts include the following:</p><p class="bulletIndent1"><span class="glyph">●</span>Drug eruptions – Diffuse maculopapular drug rashes are particularly common in patients with protracted neutropenia who require long-term antibiotic therapy for neutropenic fever. These are often attributed to chemotherapy (especially <a class="drug drug_general" data-topicid="9314" href="/z/d/drug information/9314.html" rel="external">cytarabine</a>), beta-lactam antibiotics, <a class="drug drug_general" data-topicid="10037" href="/z/d/drug information/10037.html" rel="external">vancomycin</a>, and other agents, although it is often difficult to identify a cause in the setting of multiple concomitant therapies. (See  <a class="medical medical_review" href="/z/d/html/2089.html" rel="external">"Drug eruptions"</a>.)</p><p></p><p class="bulletIndent1">Skin lesions accompanied by fever (often relatively high fever) are also features of severe drug reactions, specifically drug reaction with eosinophilia and systemic symptoms (DRESS), Stevens Johnson syndrome, and toxic epidermal necrolysis. These rare reactions typically develop one to three weeks after the initiation of the culprit agent. (See  <a class="medical medical_review" href="/z/d/html/16420.html" rel="external">"Drug reaction with eosinophilia and systemic symptoms (DRESS)"</a> and  <a class="medical medical_review" href="/z/d/html/2091.html" rel="external">"Stevens-Johnson syndrome and toxic epidermal necrolysis: Pathogenesis, clinical manifestations, and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Graft-versus-host disease. (See  <a class="medical medical_review" href="/z/d/html/3549.html" rel="external">"Clinical manifestations, diagnosis, and grading of acute graft-versus-host disease", section on 'Skin'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Sweet syndrome. (See  <a class="medical medical_review" href="/z/d/html/13784.html" rel="external">"Sweet syndrome (acute febrile neutrophilic dermatosis): Pathogenesis, clinical manifestations, and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Vasculitis. (See  <a class="medical medical_review" href="/z/d/html/13769.html" rel="external">"Evaluation of adults with cutaneous lesions of vasculitis"</a> and  <a class="medical medical_review" href="/z/d/html/8241.html" rel="external">"Overview of cutaneous small vessel vasculitis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Leukemia cutis. (See  <a class="medical medical_review" href="/z/d/html/4497.html" rel="external">"Clinical manifestations, pathologic features, and diagnosis of acute myeloid leukemia", section on 'Skin'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Cutaneous lymphoma. (See  <a class="medical medical_review" href="/z/d/html/15541.html" rel="external">"Approach to the patient with a diagnosis of atypical lymphocytic infiltrate of the skin"</a> and  <a class="medical medical_review" href="/z/d/html/4715.html" rel="external">"Primary cutaneous large B cell lymphoma, leg type"</a> and  <a class="medical medical_review" href="/z/d/html/4718.html" rel="external">"Primary cutaneous follicle center lymphoma"</a> and  <a class="medical medical_review" href="/z/d/html/1674.html" rel="external">"Clinical manifestations, pathologic features, and diagnosis of mycosis fungoides"</a> and  <a class="medical medical_review" href="/z/d/html/4739.html" rel="external">"Primary cutaneous marginal zone lymphoma"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Pyoderma gangrenosum. (See  <a class="medical medical_review" href="/z/d/html/13782.html" rel="external">"Pyoderma gangrenosum: Pathogenesis, clinical features, and diagnosis"</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Engraftment syndrome following hematopoietic cell transplantation – Skin rash, fever, and sometimes organ dysfunction and a capillary leak syndrome can be seen in engraftment syndrome after autologous stem cell transplantation or, less commonly, after allogeneic hematopoietic cell transplantation. (See  <a class="medical medical_review" href="/z/d/html/4342.html" rel="external">"Pulmonary complications after autologous hematopoietic cell transplantation", section on 'Engraftment syndrome and PERDS'</a> and  <a class="medical medical_review" href="/z/d/html/4339.html" rel="external">"Pulmonary complications after allogeneic hematopoietic cell transplantation: Causes", section on 'Engraftment syndrome'</a>.)</p><p></p><p class="headingAnchor" id="H49968530"><span class="h1">SUMMARY</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Types of immunocompromise</strong> − Immunocompromising diseases can cause multiple defects in host defenses, which, in turn, lead to heightened susceptibility to various types of infections. Knowledge of these immune defects and the specific associated infections can assist the clinician in the initial evaluation and management of the immunocompromised patient with skin lesions. These lesions sometimes reflect disseminated infection; evaluation of the skin may provide the most rapid diagnosis and thus may be lifesaving. (See <a class="local">'Introduction'</a> above and <a class="local">'Types of immunocompromise'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Bacterial infections</strong> </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><em>Pseudomonas aeruginosa</em> is a feared nosocomial pathogen in immunocompromised hosts, particularly in those who are neutropenic. Cutaneous manifestations of pseudomonal bacteremia reportedly occur in almost one-third of cases; lesions in immunocompromised hosts include abscesses, folliculitis, cellulitis, vesicles, maculopapular or subcutaneous nodules, plaques, bullae, pustules, petechiae, and ecthyma gangrenosum. (See <a class="local">'Pseudomonas aeruginosa'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Other bacterial species that can cause rash and fever in neutropenic patients include <em>Stenotrophomonas maltophilia</em>, <em>Aeromonas hydrophila</em>, <em>Streptococcus viridans</em>, and clostridial species as well as <em>Nocardia</em> spp and mycobacteria. (See <a class="local">'Bacterial infections'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Fungal infections</strong> </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Important causes of fungal infection are broadly divided into the categories of yeasts (including <em>Candida</em> spp, <em>Cryptococcus</em> spp, <em>Trichosporon</em> spp), molds (including <em>Aspergillus</em> spp, <em>Fusarium</em> spp, the agents of mucormycosis, dematiaceous fungi, and dermatophytes), and dimorphic fungi (including the endemic mycoses due to <em>Histoplasma capsulatum</em>, <em>Coccidioides </em>spp, <em>Blastomyces dermatitidis, Paracoccidioides </em>spp, and <em>Talaromyces marneffei</em>). (See <a class="local">'Fungal infections'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Patients with neutropenia due to cancer chemotherapy are particularly susceptible to invasive fungal infections, especially those with neutropenia of greater than seven days' duration and with profound neutropenia (neutrophil count &lt;100 cells/uL). <em>Candida </em>spp and <em>Aspergillus </em>spp account for most invasive fungal infections during neutropenia. (See <a class="local">'Candida species'</a> above and <a class="local">'Aspergillus species'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Viral infections</strong> </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Common viral causes of fever and rash include herpes simplex virus and varicella-zoster virus. (See <a class="local">'Herpes simplex virus and varicella-zoster virus'</a> above.) </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Other viruses that can cause skin manifestations in immunocompromised hosts include hepatitis B virus, cytomegalovirus (ulcerations, nodules, maculopapular rash, vesicles), molluscum contagiosum (umbilicated papules/vesicles), human papillomavirus (verrucous lesions), Epstein-Barr virus (in the form of posttransplant lymphoproliferative disease), and human herpesvirus (HHV-) 8 (in the form of Kaposi sarcoma). (See <a class="local">'Hepatitis B virus'</a> above and <a class="local">'Other viruses'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Viruses that can cause acute fever and rash in any host, including immunocompromised hosts, include HHV-6 and HHV-7 (roseola), measles, rubella, and parvovirus. (See <a class="local">'Other viruses'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Additional viruses that can cause fever and rash in any host and that are associated with specific geographic regions include dengue, chikungunya, Zika virus, Ebola virus, and other causes of hemorrhagic fever. (See <a class="local">'Other viruses'</a> above.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Noninfectious causes</strong> − Important noninfectious causes of fever and rash in immunocompromised hosts include drug eruptions, graft-versus-host disease, Sweet syndrome, vasculitis, leukemia cutis, cutaneous lymphoma, pyoderma gangrenosum, and engraftment syndrome following hematopoietic cell transplantation. (See <a class="local">'Noninfectious causes'</a> above.)</p><p></p><p class="headingAnchor" id="H1074002324"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Kieren A Marr, MD, who contributed to an earlier version of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Donowitz GR. Fever in the compromised host. Infect Dis Clin North Am 1996; 10:129.</a></li><li><a class="nounderline abstract_t">Wolfson JS, Sober AJ, Rubin RH. Dermatologic manifestations of infections in immunocompromised patients. Medicine (Baltimore) 1985; 64:115.</a></li><li><a class="nounderline abstract_t">Moffarah AS, Al Mohajer M, Hurwitz BL, Armstrong DG. Skin and Soft Tissue Infections. Microbiol Spectr 2016; 4.</a></li><li><a class="nounderline abstract_t">Hermaszewski RA, Webster AD. Primary hypogammaglobulinaemia: a survey of clinical manifestations and complications. Q J Med 1993; 86:31.</a></li><li><a class="nounderline abstract_t">Casulo C, Maragulia J, Zelenetz AD. Incidence of hypogammaglobulinemia in patients receiving rituximab and the use of intravenous immunoglobulin for recurrent infections. Clin Lymphoma Myeloma Leuk 2013; 13:106.</a></li><li><a class="nounderline abstract_t">Wara DW. Host defense against Streptococcus pneumoniae: the role of the spleen. Rev Infect Dis 1981; 3:299.</a></li><li><a class="nounderline abstract_t">Cunha BA. Infections and asplenia. Infect Dis Pract 1997; 21:48.</a></li><li><a class="nounderline abstract_t">Wallis RS, Broder MS, Wong JY, et al. Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin Infect Dis 2004; 38:1261.</a></li><li><a class="nounderline abstract_t">Crum NF, Lederman ER, Wallace MR. Infections associated with tumor necrosis factor-alpha antagonists. Medicine (Baltimore) 2005; 84:291.</a></li><li><a class="nounderline abstract_t">Nyboe Andersen N, Pasternak B, Friis-Møller N, et al. Association between tumour necrosis factor-α inhibitors and risk of serious infections in people with inflammatory bowel disease: nationwide Danish cohort study. BMJ 2015; 350:h2809.</a></li><li><a class="nounderline abstract_t">Ali T, Chakraburtty A, Mahmood S, Bronze MS. Risk of nocardial infections with anti-tumor necrosis factor therapy. Am J Med Sci 2013; 346:166.</a></li><li><a class="nounderline abstract_t">Wendling D, Murad M, Mathieu S, et al. Systemic nocardiosis in a case of rheumatoid arthritis treated with tumor necrosis factor blockers. J Rheumatol 2008; 35:539.</a></li><li><a class="nounderline abstract_t">Mohan AK, Coté TR, Block JA, et al. Tuberculosis following the use of etanercept, a tumor necrosis factor inhibitor. Clin Infect Dis 2004; 39:295.</a></li><li><a class="nounderline abstract_t">Centers for Disease Control and Prevention (CDC). Tuberculosis associated with blocking agents against tumor necrosis factor-alpha--California, 2002-2003. MMWR Morb Mortal Wkly Rep 2004; 53:683.</a></li><li><a class="nounderline abstract_t">Winthrop KL, Chang E, Yamashita S, et al. Nontuberculous mycobacteria infections and anti-tumor necrosis factor-alpha therapy. Emerg Infect Dis 2009; 15:1556.</a></li><li><a class="nounderline abstract_t">Winthrop KL, Yamashita S, Beekmann SE, et al. Mycobacterial and other serious infections in patients receiving anti-tumor necrosis factor and other newly approved biologic therapies: case finding through the Emerging Infections Network. Clin Infect Dis 2008; 46:1738.</a></li><li><a class="nounderline abstract_t">True DG, Penmetcha M, Peckham SJ. Disseminated cryptococcal infection in rheumatoid arthritis treated with methotrexate and infliximab. J Rheumatol 2002; 29:1561.</a></li><li><a class="nounderline abstract_t">Arnaud L, Sene D, Costedoat-Chalumeau N, et al. Disseminated cryptococcal infection and anti-tumor necrosis factor-alpha treatment for refractory sarcoidosis: an expected association? J Rheumatol 2009; 36:462.</a></li><li><a class="nounderline abstract_t">Mehta BM, Hashkes PJ, Avery R, Deal CL. A 21-year-old man with Still's disease with fever, rash, and pancytopenia. Arthritis Care Res (Hoboken) 2010; 62:575.</a></li><li><a class="nounderline abstract_t">Lee JH, Slifman NR, Gershon SK, et al. Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor alpha antagonists infliximab and etanercept. Arthritis Rheum 2002; 46:2565.</a></li><li><a class="nounderline abstract_t">Bergstrom L, Yocum DE, Ampel NM, et al. Increased risk of coccidioidomycosis in patients treated with tumor necrosis factor alpha antagonists. Arthritis Rheum 2004; 50:1959.</a></li><li><a class="nounderline abstract_t">Hernández-Torres A, García-Vázquez E, Frías-Iniesta J, et al. Cutaneous leishmaniasis in a patient receiving infliximab. Scand J Infect Dis 2013; 45:567.</a></li><li><a class="nounderline abstract_t">Zanger P, Kötter I, Kremsner PG, Gabrysch S. Tumor necrosis factor alpha antagonist drugs and leishmaniasis in Europe. Clin Microbiol Infect 2012; 18:670.</a></li><li><a class="nounderline abstract_t">Salmon-Ceron D, Tubach F, Lortholary O, et al. Drug-specific risk of non-tuberculosis opportunistic infections in patients receiving anti-TNF therapy reported to the 3-year prospective French RATIO registry. Ann Rheum Dis 2011; 70:616.</a></li><li><a class="nounderline abstract_t">Tsiodras S, Samonis G, Boumpas DT, Kontoyiannis DP. Fungal infections complicating tumor necrosis factor alpha blockade therapy. Mayo Clin Proc 2008; 83:181.</a></li><li><a class="nounderline abstract_t">Lee CC, Chi CH, Lee NY, et al. Necrotizing fasciitis in patients with liver cirrhosis: predominance of monomicrobial Gram-negative bacillary infections. Diagn Microbiol Infect Dis 2008; 62:219.</a></li><li><a class="nounderline abstract_t">Joshi N, Caputo GM, Weitekamp MR, Karchmer AW. Infections in patients with diabetes mellitus. N Engl J Med 1999; 341:1906.</a></li><li><a class="nounderline abstract_t">Delamaire M, Maugendre D, Moreno M, et al. Impaired leucocyte functions in diabetic patients. Diabet Med 1997; 14:29.</a></li><li><a class="nounderline abstract_t">Laucks SS 2nd. Fournier's gangrene. Surg Clin North Am 1994; 74:1339.</a></li><li><a class="nounderline abstract_t">Roden MM, Zaoutis TE, Buchanan WL, et al. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. Clin Infect Dis 2005; 41:634.</a></li><li><a class="nounderline abstract_t">Adam RD, Hunter G, DiTomasso J, Comerci G Jr. Mucormycosis: emerging prominence of cutaneous infections. Clin Infect Dis 1994; 19:67.</a></li><li><a class="nounderline abstract_t">Klein NC, Cunha BA. Infections in systemic lupus erythematosus. Infectious Diseases in Clinical Practice 1999; 8:225.</a></li><li><a class="nounderline abstract_t">Cuchacovich R, Gedalia A. Pathophysiology and clinical spectrum of infections in systemic lupus erythematosus. Rheum Dis Clin North Am 2009; 35:75.</a></li><li><a class="nounderline abstract_t">Nived O, Sturfelt G, Wollheim F. Systemic lupus erythematosus and infection: a controlled and prospective study including an epidemiological group. Q J Med 1985; 55:271.</a></li><li><a class="nounderline abstract_t">Petri M. Infection in systemic lupus erythematosus. Rheum Dis Clin North Am 1998; 24:423.</a></li><li><a class="nounderline abstract_t">Zhou WJ, Yang CD. The causes and clinical significance of fever in systemic lupus erythematosus: a retrospective study of 487 hospitalised patients. Lupus 2009; 18:807.</a></li><li><a class="nounderline abstract_t">Mendez EA, Espinoza LM, Harris M, et al. Systemic lupus erythematosus complicated by necrotizing fasciitis. Lupus 1999; 8:157.</a></li><li><a class="nounderline abstract_t">Parada JP, Maslow JN. Clinical syndromes associated with adult pneumococcal cellulitis. Scand J Infect Dis 2000; 32:133.</a></li><li><a class="nounderline abstract_t">Page KR, Karakousis PC, Maslow JN. Postoperative pneumococcal cellulitis in systemic lupus erythematosus. Scand J Infect Dis 2003; 35:141.</a></li><li><a class="nounderline abstract_t">Hill MD, Karsh J. Invasive soft tissue infections with Streptococcus pneumoniae in patients with systemic lupus erythematosus: case report and review of the literature. Arthritis Rheum 1997; 40:1716.</a></li><li><a class="nounderline abstract_t">Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the infectious diseases society of America. Clin Infect Dis 2014; 59:147.</a></li><li><a class="nounderline abstract_t">Richard P, Amador Del Valle G, Moreau P, et al. Viridans streptococcal bacteraemia in patients with neutropenia. Lancet 1995; 345:1607.</a></li><li><a class="nounderline abstract_t">Engelhard D, Elishoov H, Or R, et al. Cytosine arabinoside as a major risk factor for Streptococcus viridans septicemia following bone marrow transplantation: a 5-year prospective study. Bone Marrow Transplant 1995; 16:565.</a></li><li><a class="nounderline abstract_t">Ahmed R, Hassall T, Morland B, Gray J. Viridans streptococcus bacteremia in children on chemotherapy for cancer: an underestimated problem. Pediatr Hematol Oncol 2003; 20:439.</a></li><li><a class="nounderline abstract_t">Marron A, Carratalà J, González-Barca E, et al. Serious complications of bacteremia caused by Viridans streptococci in neutropenic patients with cancer. Clin Infect Dis 2000; 31:1126.</a></li><li><a class="nounderline abstract_t">Bodey GP. Dermatologic manifestations of infections in neutropenic patients. Infect Dis Clin North Am 1994; 8:655.</a></li><li><a class="nounderline abstract_t">Villablanca JG, Steiner M, Kersey J, et al. The clinical spectrum of infections with viridans streptococci in bone marrow transplant patients. Bone Marrow Transplant 1990; 5:387.</a></li><li><a class="nounderline abstract_t">Taylor SN, Sanders CV. Unusual manifestations of invasive pneumococcal infection. Am J Med 1999; 107:12S.</a></li><li><a class="nounderline abstract_t">Patel M, Ahrens JC, Moyer DV, DiNubile MJ. Pneumococcal soft-tissue infections: a problem deserving more recognition. Clin Infect Dis 1994; 19:149.</a></li><li><a class="nounderline abstract_t">Farley MM. Group B streptococcal disease in nonpregnant adults. Clin Infect Dis 2001; 33:556.</a></li><li><a class="nounderline abstract_t">Skoff TH, Farley MM, Petit S, et al. Increasing burden of invasive group B streptococcal disease in nonpregnant adults, 1990-2007. Clin Infect Dis 2009; 49:85.</a></li><li><a class="nounderline abstract_t">Bodey GP, Rodriguez S, Fainstein V, Elting LS. Clostridial bacteremia in cancer patients. A 12-year experience. Cancer 1991; 67:1928.</a></li><li><a class="nounderline abstract_t">Pelletier JP, Plumbley JA, Rouse EA, Cina SJ. The role of Clostridium septicum in paraneoplastic sepsis. Arch Pathol Lab Med 2000; 124:353.</a></li><li><a class="nounderline abstract_t">Simon TG, Bradley J, Jones A, Carino G. Massive intravascular hemolysis from Clostridium perfringens septicemia: a review. J Intensive Care Med 2014; 29:327.</a></li><li><a class="nounderline abstract_t">Stevens DL, Aldape MJ, Bryant AE. Life-threatening clostridial infections. Anaerobe 2012; 18:254.</a></li><li><a class="nounderline abstract_t">Chatzinikolaou I, Abi-Said D, Bodey GP, et al. Recent experience with Pseudomonas aeruginosa bacteremia in patients with cancer: Retrospective analysis of 245 episodes. Arch Intern Med 2000; 160:501.</a></li><li><a class="nounderline abstract_t">Ramphal R. Changes in the etiology of bacteremia in febrile neutropenic patients and the susceptibilities of the currently isolated pathogens. Clin Infect Dis 2004; 39 Suppl 1:S25.</a></li><li><a class="nounderline abstract_t">Bodey GP, Bolivar R, Fainstein V, Jadeja L. Infections caused by Pseudomonas aeruginosa. Rev Infect Dis 1983; 5:279.</a></li><li><a class="nounderline abstract_t">Bagel J, Grossman ME. Subcutaneous nodules in Pseudomonas sepsis. Am J Med 1986; 80:528.</a></li><li><a class="nounderline abstract_t">Agger WA, Mardan A. Pseudomonas aeruginosa infections of intact skin. Clin Infect Dis 1995; 20:302.</a></li><li><a class="nounderline abstract_t">el Baze P, Thyss A, Vinti H, et al. A study of nineteen immunocompromised patients with extensive skin lesions caused by Pseudomonas aeruginosa with and without bacteremia. Acta Derm Venereol 1991; 71:411.</a></li><li><a class="nounderline abstract_t">Reisman JS, Weinberg A, Ponte C, Kradin R. Monomicrobial Pseudomonas necrotizing fasciitis: a case of infection by two strains and a review of 37 cases in the literature. Scand J Infect Dis 2012; 44:216.</a></li><li><a class="nounderline abstract_t">Fine JD, Miller JA, Harrist TJ, Haynes HA. Cutaneous lesions in disseminated candidiasis mimicking ecthyma gangrenosum. Am J Med 1981; 70:1133.</a></li><li><a class="nounderline abstract_t">Huminer D, Siegman-Igra Y, Morduchowicz G, Pitlik SD. Ecthyma gangrenosum without bacteremia. Report of six cases and review of the literature. Arch Intern Med 1987; 147:299.</a></li><li><a class="nounderline abstract_t">Reich HL, Williams Fadeyi D, Naik NS, et al. Nonpseudomonal ecthyma gangrenosum. J Am Acad Dermatol 2004; 50:S114.</a></li><li><a class="nounderline abstract_t">Son YM, Na SY, Lee HY, et al. Ecthyma Gangrenosum: A Rare Cutaneous Manifestation Caused by Stenotrophomonas maltophilia in a Leukemic Patient. Ann Dermatol 2009; 21:389.</a></li><li><a class="nounderline abstract_t">Kimyai-Asadi A, Tausk FA, Nousari HC. Ecthyma secondary to herpes simplex virus infection. Clin Infect Dis 1999; 29:454.</a></li><li><a class="nounderline abstract_t">Vaiman M, Lazarovitch T, Heller L, Lotan G. Ecthyma gangrenosum and ecthyma-like lesions: review article. Eur J Clin Microbiol Infect Dis 2015; 34:633.</a></li><li><a class="nounderline abstract_t">Fergie JE, Patrick CC, Lott L. Pseudomonas aeruginosa cellulitis and ecthyma gangrenosum in immunocompromised children. Pediatr Infect Dis J 1991; 10:496.</a></li><li><a class="nounderline abstract_t">Song WK, Kim YC, Park HJ, Cinn YW. Ecthyma gangrenosum without bacteraemia in a leukaemic patient. Clin Exp Dermatol 2001; 26:395.</a></li><li><a class="nounderline abstract_t">Vartivarian SE, Papadakis KA, Palacios JA, et al. Mucocutaneous and soft tissue infections caused by Xanthomonas maltophilia. A new spectrum. Ann Intern Med 1994; 121:969.</a></li><li><a class="nounderline abstract_t">Elting LS, Bodey GP. Septicemia due to Xanthomonas species and non-aeruginosa Pseudomonas species: increasing incidence of catheter-related infections. Medicine (Baltimore) 1990; 69:296.</a></li><li><a class="nounderline abstract_t">Moser C, Jønsson V, Thomsen K, et al. Subcutaneous lesions and bacteraemia due to Stenotrophomonas maltophilia in three leukaemic patients with neutropenia. Br J Dermatol 1997; 136:949.</a></li><li><a class="nounderline abstract_t">Micozzi A, Venditti M, Monaco M, et al. Bacteremia due to Stenotrophomonas maltophilia in patients with hematologic malignancies. Clin Infect Dis 2000; 31:705.</a></li><li><a class="nounderline abstract_t">Bin Abdulhak AA, Zimmerman V, Al Beirouti BT, et al. Stenotrophomonas maltophilia infections of intact skin: a systematic review of the literature. Diagn Microbiol Infect Dis 2009; 63:330.</a></li><li><a class="nounderline abstract_t">Baumrin E, Piette EW, Micheletti RG. Stenotrophomonas maltophilia: an emerging multidrug-resistant opportunistic pathogen in the immunocompromised host. BMJ Case Rep 2017; 2017.</a></li><li><a class="nounderline abstract_t">Shapiro RL, Altekruse S, Hutwagner L, et al. The role of Gulf Coast oysters harvested in warmer months in Vibrio vulnificus infections in the United States, 1988-1996. Vibrio Working Group. J Infect Dis 1998; 178:752.</a></li><li><a class="nounderline abstract_t">Gulig PA, Bourdage KL, Starks AM. Molecular Pathogenesis of Vibrio vulnificus. J Microbiol 2005; 43 Spec No:118.</a></li><li><a class="nounderline abstract_t">Centers for Disease Control and Prevention (CDC). Vibrio illnesses after Hurricane Katrina--multiple states, August-September 2005. MMWR Morb Mortal Wkly Rep 2005; 54:928.</a></li><li><a class="nounderline abstract_t">Daniels NA, MacKinnon L, Bishop R, et al. Vibrio parahaemolyticus infections in the United States, 1973-1998. J Infect Dis 2000; 181:1661.</a></li><li><a class="nounderline abstract_t">Klontz KC, Lieb S, Schreiber M, et al. Syndromes of Vibrio vulnificus infections. Clinical and epidemiologic features in Florida cases, 1981-1987. Ann Intern Med 1988; 109:318.</a></li><li><a class="nounderline abstract_t">Lin CS, Cheng SH. Aeromonas hydrophila sepsis presenting as meningitis and necrotizing fasciitis in a man with alcoholic liver cirrhosis. J Formos Med Assoc 1998; 97:498.</a></li><li><a class="nounderline abstract_t">Janda JM, Abbott SL. Evolving concepts regarding the genus Aeromonas: an expanding Panorama of species, disease presentations, and unanswered questions. Clin Infect Dis 1998; 27:332.</a></li><li><a class="nounderline abstract_t">Lau SM, Peng MY, Chang FY. Outcomes of Aeromonas bacteremia in patients with different types of underlying disease. J Microbiol Immunol Infect 2000; 33:241.</a></li><li><a class="nounderline abstract_t">Kalb RE, Kaplan MH, Grossman ME. Cutaneous nocardiosis. Case reports and review. J Am Acad Dermatol 1985; 13:125.</a></li><li><a class="nounderline abstract_t">Georghiou PR, Blacklock ZM. Infection with Nocardia species in Queensland. A review of 102 clinical isolates. Med J Aust 1992; 156:692.</a></li><li><a class="nounderline abstract_t">Haussaire D, Fournier PE, Djiguiba K, et al. Nocardiosis in the south of France over a 10-years period, 2004-2014. Int J Infect Dis 2017; 57:13.</a></li><li><a class="nounderline abstract_t">Hemmersbach-Miller M, Catania J, Saullo JL. Updates on Nocardia Skin and Soft Tissue Infections in Solid Organ Transplantation. Curr Infect Dis Rep 2019; 21:27.</a></li><li><a class="nounderline abstract_t">Shannon K, Pasikhova Y, Ibekweh Q, et al. Nocardiosis following hematopoietic stem cell transplantation. Transpl Infect Dis 2016; 18:169.</a></li><li><a class="nounderline abstract_t">Coussement J, Lebeaux D, van Delden C, et al. Nocardia Infection in Solid Organ Transplant Recipients: A Multicenter European Case-control Study. Clin Infect Dis 2016; 63:338.</a></li><li><a class="nounderline abstract_t">Franco-Paredes C, Marcos LA, Henao-Martínez AF, et al. Cutaneous Mycobacterial Infections. Clin Microbiol Rev 2018; 32.</a></li><li class="breakAll">Tappeiner G, Wolff K. Tuberculosis and Other Mycobacterial Infections. In: Dermatology in General Medicine, 5th ed, Fitzpatrick TB, Eisen AZ, Wolff K, et al (Eds), McGraw Hill, New York 1999. p.2274.</li><li><a class="nounderline abstract_t">Barbagallo J, Tager P, Ingleton R, et al. Cutaneous tuberculosis: diagnosis and treatment. Am J Clin Dermatol 2002; 3:319.</a></li><li><a class="nounderline abstract_t">Asnis DS, Bresciani AR. Cutaneous tuberculosis: a rare presentation of malignancy. Clin Infect Dis 1992; 15:158.</a></li><li class="breakAll">Johnson RA, Avram M, Chan E. Skin infections in the immunocompromised host-NonHIV. In: The Skin and Infection: A Color Atlas and Text, Sanders CV, Nesbitt LT Jr (Eds), Williams and Wilkins, Baltimore 1995. p.254.</li><li><a class="nounderline abstract_t">Street ML, Umbert-Millet IJ, Roberts GD, Su WP. Nontuberculous mycobacterial infections of the skin. Report of fourteen cases and review of the literature. J Am Acad Dermatol 1991; 24:208.</a></li><li><a class="nounderline abstract_t">Pandian TK, Deziel PJ, Otley CC, et al. Mycobacterium marinum infections in transplant recipients: case report and review of the literature. Transpl Infect Dis 2008; 10:358.</a></li><li><a class="nounderline abstract_t">Stengem J, Grande KK, Hsu S. Localized primary cutaneous Mycobacterium kansasii infection in an immunocompromised patient. J Am Acad Dermatol 1999; 41:854.</a></li><li><a class="nounderline abstract_t">Kristjansson M, Bieluch VM, Byeff PD. Mycobacterium haemophilum infection in immunocompromised patients: case report and review of the literature. Rev Infect Dis 1991; 13:906.</a></li><li><a class="nounderline abstract_t">Nookeu P, Angkasekwinai N, Foongladda S, Phoompoung P. Clinical Characteristics and Treatment Outcomes for Patients Infected with Mycobacterium haemophilum. Emerg Infect Dis 2019; 25:1648.</a></li><li><a class="nounderline abstract_t">Shah MK, Sebti A, Kiehn TE, et al. Mycobacterium haemophilum in immunocompromised patients. Clin Infect Dis 2001; 33:330.</a></li><li><a class="nounderline abstract_t">Straus WL, Ostroff SM, Jernigan DB, et al. Clinical and epidemiologic characteristics of Mycobacterium haemophilum, an emerging pathogen in immunocompromised patients. Ann Intern Med 1994; 120:118.</a></li><li><a class="nounderline abstract_t">Swetter SM, Kindel SE, Smoller BR. Cutaneous nodules of Mycobacterium chelonae in an immunosuppressed patient with preexisting pulmonary colonization. J Am Acad Dermatol 1993; 28:352.</a></li><li><a class="nounderline abstract_t">Patel R, Roberts GD, Keating MR, Paya CV. Infections due to nontuberculous mycobacteria in kidney, heart, and liver transplant recipients. Clin Infect Dis 1994; 19:263.</a></li><li><a class="nounderline abstract_t">Hoffman PC, Fraser DW, Robicsek F, et al. Two outbreaks of sternal wound infection due to organisms of the Mycobacterium fortuitum complex. J Infect Dis 1981; 143:533.</a></li><li><a class="nounderline abstract_t">Horsburgh CR Jr, Mason UG 3rd, Farhi DC, Iseman MD. Disseminated infection with Mycobacterium avium-intracellulare. A report of 13 cases and a review of the literature. Medicine (Baltimore) 1985; 64:36.</a></li><li><a class="nounderline abstract_t">Kollipara R, Richards K, Tschen J, et al. Disseminated Mycobacterium avium Complex With Cutaneous Lesions. J Cutan Med Surg 2016; 20:272.</a></li><li><a class="nounderline abstract_t">Maddy AJ, Sanchez N, Shukla BS, Maderal AD. Dermatological manifestations of fungal infection in patients with febrile neutropaenia: A review of the literature. Mycoses 2019; 62:826.</a></li><li><a class="nounderline abstract_t">Swerdloff JN, Filler SG, Edwards JE Jr. Severe candidal infections in neutropenic patients. Clin Infect Dis 1993; 17 Suppl 2:S457.</a></li><li><a class="nounderline abstract_t">Guarana M, Nucci M. Acute disseminated candidiasis with skin lesions: a systematic review. Clin Microbiol Infect 2018; 24:246.</a></li><li><a class="nounderline abstract_t">Bodey GP, Luna M. Skin lesions associated with disseminated candidiasis. JAMA 1974; 229:1466.</a></li><li><a class="nounderline abstract_t">Walsh TJ, Newman KR, Moody M, et al. Trichosporonosis in patients with neoplastic disease. Medicine (Baltimore) 1986; 65:268.</a></li><li><a class="nounderline abstract_t">Girmenia C, Pagano L, Martino B, et al. Invasive infections caused by Trichosporon species and Geotrichum capitatum in patients with hematological malignancies: a retrospective multicenter study from Italy and review of the literature. J Clin Microbiol 2005; 43:1818.</a></li><li><a class="nounderline abstract_t">Fournier S, Pavageau W, Feuillhade M, et al. Use of voriconazole to successfully treat disseminated Trichosporon asahii infection in a patient with acute myeloid leukaemia. Eur J Clin Microbiol Infect Dis 2002; 21:892.</a></li><li><a class="nounderline abstract_t">Pema K, Diaz J, Guerra LG, et al. Disseminated cutaneous cryptococcosis. Comparison of clinical manifestations in the pre-AIDS and AIDS eras. Arch Intern Med 1994; 154:1032.</a></li><li><a class="nounderline abstract_t">Neuville S, Dromer F, Morin O, et al. Primary cutaneous cryptococcosis: a distinct clinical entity. Clin Infect Dis 2003; 36:337.</a></li><li><a class="nounderline abstract_t">Anderson DJ, Schmidt C, Goodman J, Pomeroy C. Cryptococcal disease presenting as cellulitis. Clin Infect Dis 1992; 14:666.</a></li><li><a class="nounderline abstract_t">Pagano L, Fianchi L, Caramatti C, et al. Cryptococcosis in patients with hematologic malignancies. A report from GIMEMA-infection. Haematologica 2004; 89:852.</a></li><li><a class="nounderline abstract_t">Abuav R, McGirt LY, Kazin RA. Cryptococcal panniculitis in an immunocompromised patient: a case report and review of the literature. Cutis 2010; 85:303.</a></li><li><a class="nounderline abstract_t">Sun HY, Alexander BD, Lortholary O, et al. Cutaneous cryptococcosis in solid organ transplant recipients. Med Mycol 2010; 48:785.</a></li><li><a class="nounderline abstract_t">Biancheri D, Kanitakis J, Bienvenu AL, et al. Cutaneous cryptococcosis in solid organ transplant recipients: epidemiological, clinical, diagnostic and therapeutic features. Eur J Dermatol 2012; 22:651.</a></li><li><a class="nounderline abstract_t">Baer S, Baddley JW, Gnann JW, Pappas PG. Cryptococcal disease presenting as necrotizing cellulitis in transplant recipients. Transpl Infect Dis 2009; 11:353.</a></li><li><a class="nounderline abstract_t">Galimberti R, Kowalczuk A, Hidalgo Parra I, et al. Cutaneous aspergillosis: a report of six cases. Br J Dermatol 1998; 139:522.</a></li><li><a class="nounderline abstract_t">Mert D, Iskender G, Duygu F, et al. Invasive Aspergillosis with Disseminated Skin Involvement in a Patient with Acute Myeloid Leukemia: A Rare Case. Hematol Rep 2017; 9:6997.</a></li><li><a class="nounderline abstract_t">Bernardeschi C, Foulet F, Ingen-Housz-Oro S, et al. Cutaneous Invasive Aspergillosis: Retrospective Multicenter Study of the French Invasive-Aspergillosis Registry and Literature Review. Medicine (Baltimore) 2015; 94:e1018.</a></li><li><a class="nounderline abstract_t">Allo MD, Miller J, Townsend T, Tan C. Primary cutaneous aspergillosis associated with Hickman intravenous catheters. N Engl J Med 1987; 317:1105.</a></li><li><a class="nounderline abstract_t">Walsh TJ. Primary cutaneous aspergillosis--an emerging infection among immunocompromised patients. Clin Infect Dis 1998; 27:453.</a></li><li><a class="nounderline abstract_t">Tatara AM, Mikos AG, Kontoyiannis DP. Factors affecting patient outcome in primary cutaneous aspergillosis. Medicine (Baltimore) 2016; 95:e3747.</a></li><li><a class="nounderline abstract_t">van Burik JA, Colven R, Spach DH. Cutaneous aspergillosis. J Clin Microbiol 1998; 36:3115.</a></li><li><a class="nounderline abstract_t">Isaac M. Cutaneous aspergillosis. Dermatol Clin 1996; 14:137.</a></li><li><a class="nounderline abstract_t">Petrikkos G, Skiada A, Lortholary O, et al. Epidemiology and clinical manifestations of mucormycosis. Clin Infect Dis 2012; 54 Suppl 1:S23.</a></li><li><a class="nounderline abstract_t">Ribes JA, Vanover-Sams CL, Baker DJ. Zygomycetes in human disease. Clin Microbiol Rev 2000; 13:236.</a></li><li><a class="nounderline abstract_t">Wirth F, Perry R, Eskenazi A, et al. Cutaneous mucormycosis with subsequent visceral dissemination in a child with neutropenia: a case report and review of the pediatric literature. J Am Acad Dermatol 1997; 36:336.</a></li><li><a class="nounderline abstract_t">Stempel JM, Hammond SP, Sutton DA, et al. Invasive Fusariosis in the Voriconazole Era: Single-Center 13-Year Experience. Open Forum Infect Dis 2015; 2:ofv099.</a></li><li><a class="nounderline abstract_t">Nucci M, Anaissie E. Cutaneous infection by Fusarium species in healthy and immunocompromised hosts: implications for diagnosis and management. Clin Infect Dis 2002; 35:909.</a></li><li><a class="nounderline abstract_t">Boutati EI, Anaissie EJ. Fusarium, a significant emerging pathogen in patients with hematologic malignancy: ten years' experience at a cancer center and implications for management. Blood 1997; 90:999.</a></li><li><a class="nounderline abstract_t">Bodey GP, Boktour M, Mays S, et al. Skin lesions associated with Fusarium infection. J Am Acad Dermatol 2002; 47:659.</a></li><li><a class="nounderline abstract_t">Fishman JA. Overview: fungal infections in the transplant patient. Transpl Infect Dis 2002; 4 Suppl 3:3.</a></li><li><a class="nounderline abstract_t">Campagnaro EL, Woodside KJ, Early MG, et al. Disseminated Pseudallescheria boydii (Scedosporium apiospermum) infection in a renal transplant patient. Transpl Infect Dis 2002; 4:207.</a></li><li><a class="nounderline abstract_t">Nucci M, Anaissie E. Fusarium infections in immunocompromised patients. Clin Microbiol Rev 2007; 20:695.</a></li><li><a class="nounderline abstract_t">McCarty TP, Baddley JW, Walsh TJ, et al. Phaeohyphomycosis in transplant recipients: Results from the Transplant Associated Infection Surveillance Network (TRANSNET). Med Mycol 2015; 53:440.</a></li><li><a class="nounderline abstract_t">Aragón-Miguel R, Calleja-Algarra A, Morales-Raya C, et al. Alternaria infectoria skin infection in a renal transplant recipient: an emerging phaeohyphomycosis of occidental countries? Int J Dermatol 2017; 56:e153.</a></li><li><a class="nounderline abstract_t">Schieffelin JS, Garcia-Diaz JB, Loss GE Jr, et al. Phaeohyphomycosis fungal infections in solid organ transplant recipients: clinical presentation, pathology, and treatment. Transpl Infect Dis 2014; 16:270.</a></li><li><a class="nounderline abstract_t">Body BA. Cutaneous manifestations of systemic mycoses. Dermatol Clin 1996; 14:125.</a></li><li><a class="nounderline abstract_t">Pappas PG, Threlkeld MG, Bedsole GD, et al. Blastomycosis in immunocompromised patients. Medicine (Baltimore) 1993; 72:311.</a></li><li><a class="nounderline abstract_t">Bradsher RW. Histoplasmosis and blastomycosis. Clin Infect Dis 1996; 22 Suppl 2:S102.</a></li><li><a class="nounderline abstract_t">Saccente M, Woods GL. Clinical and laboratory update on blastomycosis. Clin Microbiol Rev 2010; 23:367.</a></li><li><a class="nounderline abstract_t">Hobbs ER. Coccidioidomycosis. Dermatol Clin 1989; 7:227.</a></li><li><a class="nounderline abstract_t">Quimby SR, Connolly SM, Winkelmann RK, Smilack JD. Clinicopathologic spectrum of specific cutaneous lesions of disseminated coccidioidomycosis. J Am Acad Dermatol 1992; 26:79.</a></li><li><a class="nounderline abstract_t">Garcia Garcia SC, Salas Alanis JC, Flores MG, et al. Coccidioidomycosis and the skin: a comprehensive review. An Bras Dermatol 2015; 90:610.</a></li><li><a class="nounderline abstract_t">Garza-Chapa JI, Martínez-Cabriales SA, Ocampo-Garza J, et al. Cold subcutaneous abscesses as the first manifestation of disseminated coccidioidomycosis in an immunocompromised host. Australas J Dermatol 2016; 57:e49.</a></li><li><a class="nounderline abstract_t">Chang P, Rodas C. Skin lesions in histoplasmosis. Clin Dermatol 2012; 30:592.</a></li><li><a class="nounderline abstract_t">Kauffman CA, Israel KS, Smith JW, et al. Histoplasmosis in immunosuppressed patients. Am J Med 1978; 64:923.</a></li><li><a class="nounderline abstract_t">Studdard J, Sneed WF, Taylor MR Jr, Campbell GD. Cutaneous histoplasmosis. Am Rev Respir Dis 1976; 113:689.</a></li><li><a class="nounderline abstract_t">Freifeld AG, Wheat LJ, Kaul DR. Histoplasmosis in solid organ transplant recipients: early diagnosis and treatment. Curr Opin Organ Transplant 2009; 14:601.</a></li><li><a class="nounderline abstract_t">Vinicki JP, Tiraboschi IN, Fernandez D, et al. Necrotizing vasculitis secondary to disseminated histoplasmosis simulating pyoderma gangrenosum. Rheumatology (Oxford) 2013; 52:2304.</a></li><li><a class="nounderline abstract_t">Dufresne SF, LeBlanc RE, Zhang SX, et al. Histoplasmosis and subcutaneous nodules in a kidney transplant recipient: erythema nodosum versus fungal panniculitis. Transpl Infect Dis 2013; 15:E58.</a></li><li><a class="nounderline abstract_t">Romano C, Castelli A, Laurini L, Massai L. Case report. Primary cutaneous histoplasmosis in an immunosuppressed patient. Mycoses 2000; 43:151.</a></li><li><a class="nounderline abstract_t">Ramos-E-Silva M, Saraiva Ldo E. Paracoccidioidomycosis. Dermatol Clin 2008; 26:257.</a></li><li><a class="nounderline abstract_t">Shikanai-Yasuda MA, Telles Filho Fde Q, Mendes RP, et al. [Guidelines in paracoccidioidomycosis]. Rev Soc Bras Med Trop 2006; 39:297.</a></li><li><a class="nounderline abstract_t">Chan JF, Lau SK, Yuen KY, Woo PC. Talaromyces (Penicillium) marneffei infection in non-HIV-infected patients. Emerg Microbes Infect 2016; 5:e19.</a></li><li><a class="nounderline abstract_t">Kawila R, Chaiwarith R, Supparatpinyo K. Clinical and laboratory characteristics of penicilliosis marneffei among patients with and without HIV infection in Northern Thailand: a retrospective study. BMC Infect Dis 2013; 13:464.</a></li><li><a class="nounderline abstract_t">Schwartz IS, Kenyon C, Feng P, et al. 50 Years of Emmonsia Disease in Humans: The Dramatic Emergence of a Cluster of Novel Fungal Pathogens. PLoS Pathog 2015; 11:e1005198.</a></li><li><a class="nounderline abstract_t">Schwartz IS, Govender NP, Sigler L, et al. Emergomyces: The global rise of new dimorphic fungal pathogens. PLoS Pathog 2019; 15:e1007977.</a></li><li><a class="nounderline abstract_t">Heys I, Taljaard J, Orth H. An emmonsia species causing disseminated infection in South Africa. N Engl J Med 2014; 370:283.</a></li><li><a class="nounderline abstract_t">Schwartz IS, Govender NP, Corcoran C, et al. Clinical Characteristics, Diagnosis, Management, and Outcomes of Disseminated Emmonsiosis: A Retrospective Case Series. Clin Infect Dis 2015; 61:1004.</a></li><li><a class="nounderline abstract_t">Pagnoux C, Seror R, Henegar C, et al. Clinical features and outcomes in 348 patients with polyarteritis nodosa: a systematic retrospective study of patients diagnosed between 1963 and 2005 and entered into the French Vasculitis Study Group Database. Arthritis Rheum 2010; 62:616.</a></li><li><a class="nounderline abstract_t">Gibson LE, Su WP. Cutaneous vasculitis. Rheum Dis Clin North Am 1995; 21:1097.</a></li></ol></div><div id="topicVersionRevision">Topic 1409 Version 29.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8698987" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Fever in the compromised host.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3974441" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Dermatologic manifestations of infections in immunocompromised patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27726817" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Skin and Soft Tissue Infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8438047" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Primary hypogammaglobulinaemia: a survey of clinical manifestations and complications.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23276889" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Incidence of hypogammaglobulinemia in patients receiving rituximab and the use of intravenous immunoglobulin for recurrent infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7256088" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Host defense against Streptococcus pneumoniae: the role of the spleen.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Infections and asplenia</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15127338" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Granulomatous infectious diseases associated with tumor necrosis factor antagonists.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16148729" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Infections associated with tumor necrosis factor-alpha antagonists.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26048617" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Association between tumour necrosis factor-αinhibitors and risk of serious infections in people with inflammatory bowel disease: nationwide Danish cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23531994" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Risk of nocardial infections with anti-tumor necrosis factor therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18322977" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Systemic nocardiosis in a case of rheumatoid arthritis treated with tumor necrosis factor blockers.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15306993" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Tuberculosis following the use of etanercept, a tumor necrosis factor inhibitor.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15295313" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Tuberculosis associated with blocking agents against tumor necrosis factor-alpha--California, 2002-2003.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19861045" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Nontuberculous mycobacteria infections and anti-tumor necrosis factor-alpha therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18419421" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Mycobacterial and other serious infections in patients receiving anti-tumor necrosis factor and other newly approved biologic therapies: case finding through the Emerging Infections Network.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12136922" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Disseminated cryptococcal infection in rheumatoid arthritis treated with methotrexate and infliximab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19208587" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Disseminated cryptococcal infection and anti-tumor necrosis factor-alpha treatment for refractory sarcoidosis: an expected association?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20391515" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : A 21-year-old man with Still's disease with fever, rash, and pancytopenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12384912" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Life-threatening histoplasmosis complicating immunotherapy with tumor necrosis factor alpha antagonists infliximab and etanercept.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15188373" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Increased risk of coccidioidomycosis in patients treated with tumor necrosis factor alpha antagonists.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23270475" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Cutaneous leishmaniasis in a patient receiving infliximab.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21985586" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Tumor necrosis factor alpha antagonist drugs and leishmaniasis in Europe.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21177290" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Drug-specific risk of non-tuberculosis opportunistic infections in patients receiving anti-TNF therapy reported to the 3-year prospective French RATIO registry.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18241628" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Fungal infections complicating tumor necrosis factor alpha blockade therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18653302" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Necrotizing fasciitis in patients with liver cirrhosis: predominance of monomicrobial Gram-negative bacillary infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10601511" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Infections in patients with diabetes mellitus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9017350" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Impaired leucocyte functions in diabetic patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7985069" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Fournier's gangrene.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16080086" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Epidemiology and outcome of zygomycosis: a review of 929 reported cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7948560" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Mucormycosis: emerging prominence of cutaneous infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Infections in systemic lupus erythematosus</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19480998" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Pathophysiology and clinical spectrum of infections in systemic lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4023171" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Systemic lupus erythematosus and infection: a controlled and prospective study including an epidemiological group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9606766" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Infection in systemic lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19578105" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : The causes and clinical significance of fever in systemic lupus erythematosus: a retrospective study of 487 hospitalised patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10192511" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Systemic lupus erythematosus complicated by necrotizing fasciitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10826896" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Clinical syndromes associated with adult pneumococcal cellulitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12693569" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Postoperative pneumococcal cellulitis in systemic lupus erythematosus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9324028" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Invasive soft tissue infections with Streptococcus pneumoniae in patients with systemic lupus erythematosus: case report and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24947530" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Practice guidelines for the diagnosis and management of skin and soft tissue infections: 2014 update by the infectious diseases society of America.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7783538" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Viridans streptococcal bacteraemia in patients with neutropenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8528173" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Cytosine arabinoside as a major risk factor for Streptococcus viridans septicemia following bone marrow transplantation: a 5-year prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14631617" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Viridans streptococcus bacteremia in children on chemotherapy for cancer: an underestimated problem.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11073739" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Serious complications of bacteremia caused by Viridans streptococci in neutropenic patients with cancer.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7814839" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Dermatologic manifestations of infections in neutropenic patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2369679" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : The clinical spectrum of infections with viridans streptococci in bone marrow transplant patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10451005" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Unusual manifestations of invasive pneumococcal infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7948518" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Pneumococcal soft-tissue infections: a problem deserving more recognition.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11462195" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Group B streptococcal disease in nonpregnant adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19480572" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Increasing burden of invasive group B streptococcal disease in nonpregnant adults, 1990-2007.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2004306" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : Clostridial bacteremia in cancer patients. A 12-year experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10705386" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : The role of Clostridium septicum in paraneoplastic sepsis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24019300" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Massive intravascular hemolysis from Clostridium perfringens septicemia: a review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22120198" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Life-threatening clostridial infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10695690" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Recent experience with Pseudomonas aeruginosa bacteremia in patients with cancer: Retrospective analysis of 245 episodes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15250017" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : Changes in the etiology of bacteremia in febrile neutropenic patients and the susceptibilities of the currently isolated pathogens.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6405475" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Infections caused by Pseudomonas aeruginosa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3082201" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : Subcutaneous nodules in Pseudomonas sepsis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7742434" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Pseudomonas aeruginosa infections of intact skin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1684470" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : A study of nineteen immunocompromised patients with extensive skin lesions caused by Pseudomonas aeruginosa with and without bacteremia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22126406" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Monomicrobial Pseudomonas necrotizing fasciitis: a case of infection by two strains and a review of 37 cases in the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7234879" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Cutaneous lesions in disseminated candidiasis mimicking ecthyma gangrenosum.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3813747" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Ecthyma gangrenosum without bacteremia. Report of six cases and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15097944" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Nonpseudomonal ecthyma gangrenosum.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20523829" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Ecthyma Gangrenosum: A Rare Cutaneous Manifestation Caused by Stenotrophomonas maltophilia in a Leukemic Patient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10476767" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Ecthyma secondary to herpes simplex virus infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25407372" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Ecthyma gangrenosum and ecthyma-like lesions: review article.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1876464" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Pseudomonas aeruginosa cellulitis and ecthyma gangrenosum in immunocompromised children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11488824" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Ecthyma gangrenosum without bacteraemia in a leukaemic patient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7978724" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Mucocutaneous and soft tissue infections caused by Xanthomonas maltophilia. A new spectrum.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2402219" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Septicemia due to Xanthomonas species and non-aeruginosa Pseudomonas species: increasing incidence of catheter-related infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9217834" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Subcutaneous lesions and bacteraemia due to Stenotrophomonas maltophilia in three leukaemic patients with neutropenia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11017819" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : Bacteremia due to Stenotrophomonas maltophilia in patients with hematologic malignancies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19070451" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Stenotrophomonas maltophilia infections of intact skin: a systematic review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29269358" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Stenotrophomonas maltophilia: an emerging multidrug-resistant opportunistic pathogen in the immunocompromised host.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9728544" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : The role of Gulf Coast oysters harvested in warmer months in Vibrio vulnificus infections in the United States, 1988-1996. Vibrio Working Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15765065" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Molecular Pathogenesis of Vibrio vulnificus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16177685" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Vibrio illnesses after Hurricane Katrina--multiple states, August-September 2005.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10823766" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Vibrio parahaemolyticus infections in the United States, 1973-1998.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3260760" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Syndromes of Vibrio vulnificus infections. Clinical and epidemiologic features in Florida cases, 1981-1987.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9700248" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Aeromonas hydrophila sepsis presenting as meningitis and necrotizing fasciitis in a man with alcoholic liver cirrhosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9709884" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Evolving concepts regarding the genus Aeromonas: an expanding Panorama of species, disease presentations, and unanswered questions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11269369" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Outcomes of Aeromonas bacteremia in patients with different types of underlying disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3897297" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Cutaneous nocardiosis. Case reports and review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1620016" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Infection with Nocardia species in Queensland. A review of 102 clinical isolates.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28088585" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Nocardiosis in the south of France over a 10-years period, 2004-2014.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31227922" id="rid87" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>88 : Updates on Nocardia Skin and Soft Tissue Infections in Solid Organ Transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26809666" id="rid88" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>89 : Nocardiosis following hematopoietic stem cell transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27090987" id="rid89" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>90 : Nocardia Infection in Solid Organ Transplant Recipients: A Multicenter European Case-control Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30429139" id="rid90" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>91 : Cutaneous Mycobacterial Infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30429139" id="rid91" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>92 : Cutaneous Mycobacterial Infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12069638" id="rid92" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>93 : Cutaneous tuberculosis: diagnosis and treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1617055" id="rid93" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>94 : Cutaneous tuberculosis: a rare presentation of malignancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1617055" id="rid94" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>95 : Cutaneous tuberculosis: a rare presentation of malignancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2007665" id="rid95" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>96 : Nontuberculous mycobacterial infections of the skin. Report of fourteen cases and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18482202" id="rid96" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>97 : Mycobacterium marinum infections in transplant recipients: case report and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10534669" id="rid97" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>98 : Localized primary cutaneous Mycobacterium kansasii infection in an immunocompromised patient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1962107" id="rid98" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>99 : Mycobacterium haemophilum infection in immunocompromised patients: case report and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31441427" id="rid99" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>100 : Clinical Characteristics and Treatment Outcomes for Patients Infected with Mycobacterium haemophilum.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11438898" id="rid100" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>101 : Mycobacterium haemophilum in immunocompromised patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8256970" id="rid101" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>102 : Clinical and epidemiologic characteristics of Mycobacterium haemophilum, an emerging pathogen in immunocompromised patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8436657" id="rid102" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>103 : Cutaneous nodules of Mycobacterium chelonae in an immunosuppressed patient with preexisting pulmonary colonization.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7986898" id="rid103" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>104 : Infections due to nontuberculous mycobacteria in kidney, heart, and liver transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7240799" id="rid104" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>105 : Two outbreaks of sternal wound infection due to organisms of the Mycobacterium fortuitum complex.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3880852" id="rid105" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>106 : Disseminated infection with Mycobacterium avium-intracellulare. A report of 13 cases and a review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26740021" id="rid106" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>107 : Disseminated Mycobacterium avium Complex With Cutaneous Lesions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31069853" id="rid107" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>108 : Dermatological manifestations of fungal infection in patients with febrile neutropaenia: A review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8274612" id="rid108" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>109 : Severe candidal infections in neutropenic patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28847765" id="rid109" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>110 : Acute disseminated candidiasis with skin lesions: a systematic review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4408358" id="rid110" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>111 : Skin lesions associated with disseminated candidiasis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3523114" id="rid111" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>112 : Trichosporonosis in patients with neoplastic disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15815003" id="rid112" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>113 : Invasive infections caused by Trichosporon species and Geotrichum capitatum in patients with hematological malignancies: a retrospective multicenter study from Italy and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12525928" id="rid113" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>114 : Use of voriconazole to successfully treat disseminated Trichosporon asahii infection in a patient with acute myeloid leukaemia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8179447" id="rid114" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>115 : Disseminated cutaneous cryptococcosis. Comparison of clinical manifestations in the pre-AIDS and AIDS eras.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12539076" id="rid115" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>116 : Primary cutaneous cryptococcosis: a distinct clinical entity.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1562658" id="rid116" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>117 : Cryptococcal disease presenting as cellulitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15257938" id="rid117" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>118 : Cryptococcosis in patients with hematologic malignancies. A report from GIMEMA-infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20666191" id="rid118" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>119 : Cryptococcal panniculitis in an immunocompromised patient: a case report and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20100136" id="rid119" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>120 : Cutaneous cryptococcosis in solid organ transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23008283" id="rid120" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>121 : Cutaneous cryptococcosis in solid organ transplant recipients: epidemiological, clinical, diagnostic and therapeutic features.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19422669" id="rid121" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>122 : Cryptococcal disease presenting as necrotizing cellulitis in transplant recipients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9767305" id="rid122" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>123 : Cutaneous aspergillosis: a report of six cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28626542" id="rid123" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>124 : Invasive Aspergillosis with Disseminated Skin Involvement in a Patient with Acute Myeloid Leukemia: A Rare Case.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26131805" id="rid124" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>125 : Cutaneous Invasive Aspergillosis: Retrospective Multicenter Study of the French Invasive-Aspergillosis Registry and Literature Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3657878" id="rid125" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>126 : Primary cutaneous aspergillosis associated with Hickman intravenous catheters.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9770139" id="rid126" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>127 : Primary cutaneous aspergillosis--an emerging infection among immunocompromised patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27367980" id="rid127" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>128 : Factors affecting patient outcome in primary cutaneous aspergillosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9774549" id="rid128" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>129 : Cutaneous aspergillosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8821166" id="rid129" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>130 : Cutaneous aspergillosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22247442" id="rid130" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>131 : Epidemiology and clinical manifestations of mucormycosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10756000" id="rid131" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>132 : Zygomycetes in human disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9039214" id="rid132" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>133 : Cutaneous mucormycosis with subsequent visceral dissemination in a child with neutropenia: a case report and review of the pediatric literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26258156" id="rid133" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>134 : Invasive Fusariosis in the Voriconazole Era: Single-Center 13-Year Experience.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12355377" id="rid134" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>135 : Cutaneous infection by Fusarium species in healthy and immunocompromised hosts: implications for diagnosis and management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9242529" id="rid135" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>136 : Fusarium, a significant emerging pathogen in patients with hematologic malignancy: ten years' experience at a cancer center and implications for management.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12399756" id="rid136" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>137 : Skin lesions associated with Fusarium infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12486786" id="rid137" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>138 : Overview: fungal infections in the transplant patient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12535264" id="rid138" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>139 : Disseminated Pseudallescheria boydii (Scedosporium apiospermum) infection in a renal transplant patient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17934079" id="rid139" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>140 : Fusarium infections in immunocompromised patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25908651" id="rid140" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>141 : Phaeohyphomycosis in transplant recipients: Results from the Transplant Associated Infection Surveillance Network (TRANSNET).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28244068" id="rid141" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>142 : Alternaria infectoria skin infection in a renal transplant recipient: an emerging phaeohyphomycosis of occidental countries?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24628809" id="rid142" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>143 : Phaeohyphomycosis fungal infections in solid organ transplant recipients: clinical presentation, pathology, and treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8821165" id="rid143" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>144 : Cutaneous manifestations of systemic mycoses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8412644" id="rid144" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>145 : Blastomycosis in immunocompromised patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8722836" id="rid145" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>146 : Histoplasmosis and blastomycosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20375357" id="rid146" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>147 : Clinical and laboratory update on blastomycosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2670368" id="rid147" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>148 : Coccidioidomycosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1732341" id="rid148" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>149 : Clinicopathologic spectrum of specific cutaneous lesions of disseminated coccidioidomycosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26560205" id="rid149" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>150 : Coccidioidomycosis and the skin: a comprehensive review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26607200" id="rid150" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>151 : Cold subcutaneous abscesses as the first manifestation of disseminated coccidioidomycosis in an immunocompromised host.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23068146" id="rid151" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>152 : Skin lesions in histoplasmosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/350045" id="rid152" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>153 : Histoplasmosis in immunosuppressed patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1267266" id="rid153" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>154 : Cutaneous histoplasmosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19812496" id="rid154" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>155 : Histoplasmosis in solid organ transplant recipients: early diagnosis and treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23661428" id="rid155" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>156 : Necrotizing vasculitis secondary to disseminated histoplasmosis simulating pyoderma gangrenosum.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23331504" id="rid156" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>157 : Histoplasmosis and subcutaneous nodules in a kidney transplant recipient: erythema nodosum versus fungal panniculitis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10907346" id="rid157" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>158 : Case report. Primary cutaneous histoplasmosis in an immunosuppressed patient.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18346557" id="rid158" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>159 : Paracoccidioidomycosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16906260" id="rid159" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>160 : [Guidelines in paracoccidioidomycosis].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26956447" id="rid160" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>161 : Talaromyces (Penicillium) marneffei infection in non-HIV-infected patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24094273" id="rid161" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>162 : Clinical and laboratory characteristics of penicilliosis marneffei among patients with and without HIV infection in Northern Thailand: a retrospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26584311" id="rid162" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>163 : 50 Years of Emmonsia Disease in Humans: The Dramatic Emergence of a Cluster of Novel Fungal Pathogens.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31536607" id="rid163" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>164 : Emergomyces: The global rise of new dimorphic fungal pathogens.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24428484" id="rid164" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>165 : An emmonsia species causing disseminated infection in South Africa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26060283" id="rid165" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>166 : Clinical Characteristics, Diagnosis, Management, and Outcomes of Disseminated Emmonsiosis: A Retrospective Case Series.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20112401" id="rid166" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>167 : Clinical features and outcomes in 348 patients with polyarteritis nodosa: a systematic retrospective study of patients diagnosed between 1963 and 2005 and entered into the French Vasculitis Study Group Database.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8592739" id="rid167" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>168 : Cutaneous vasculitis.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
